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Parkinson’s disease (PD) is the second most common neurodegenerative disease 
worldwide and the most common movement disorder. A defining pathologic feature of 
PD is the progressive death of dopaminergic neurons in a basal ganglia nucleus termed 
the substantia nigra (SN). Another hallmark feature of PD pathology is the presence of 
Lewy bodies and Lewy neurites, which are cellular inclusions with aggregated protein 
depositions, representing pathology in neuronal cell bodies and neuritic processes. 
Recently, epidemiological and genetic studies support roles for neuroinflammation in the 
progression of PD. Two types of cells that play a critical role in regulating 
neuroinflammation are microglia and astrocytes, which are activated in the basal ganglia 
of PD patients. Studies within this dissertation characterized activation of microglial cells 
by alpha-synuclein (α-synuclein), the most abundant protein in Lewy bodies, which has 
been implicated in PD pathogenesis. To garner insights into molecular mechanisms 
associated with astrocyte proliferation and activation, genomic alterations during 
developmental stages of astrocytes were examined since they are likely to recapitulate the 
reactivity associated with gliosis in PD brain. The activation of these glial cells and 
pathology of neurons in the basal ganglia causes the hallmark symptoms of PD. The 
symptoms of PD are termed parkinsonism. These are thought to result, at least in part, 
from alterations in the balance of output of the neostriatal efferent neurons, due to the 
xvi 
 
loss of dopaminergic neuronal innervation of these cells. Phosphodiesterase 10A 
(PDE10A) is preferentially expressed in neostriatal efferent pathways and PDE10A 
inhibitors (PDE10i) have been shown to target dopamine signaling mechanisms. Studies 
here have utilized PDE10i to understand the balance of activation of medium spiny 
neurons in the indirect pathway versus activation of the direct pathway, since recent 
findings show PDE10i lead to a decrease in thalamic drive to the motor cortex, a primary 
symptom of PD. In conclusion, the aims of this dissertation sought to identify 
neuroinflammatory mechanisms within activated microglia in response to α-synuclein 
and proliferating astrocytes. Also, this work evaluated an inhibition of PDE10A in 
neurons within a region important to the progression of PD. 
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CHAPTER 1: INTRODUCTION 
Objectives 
The purpose of studies described here is to enable the characterization of 
neuroinflammation mediated by alpha-synuclein (α-synuclein), a pathological molecule 
in Parkinson’s disease (PD). Several lines of evidence implicate α-synuclein in this 
disease; however few experiments have identified key signatures of the direct toxic effect 
of α-synuclein in microglial cells while incorporating appropriate monomeric controls. 
Also, while it is known that astrocytes undergo de-differentiation and proliferation during 
reactive gliosis, it is not understood whether reactive gliosis has a representative 
expression profile or genomic modifications of a particular stage of development or if 
signaling pathways labeled “inflammatory” play a role in astrogenesis. Since current 
studies in the literature relating to astrogenesis analyses have many technical caveats, 
further systematic analyses of radial glial cells and astrocytes during proliferation and 
differentiation stages are warranted. Lastly, phosphodiesterase 10A (PDE10A) inhibitors 
(PDE10i) have been shown to activate cells within the neostriatum, a region of the brain 
associated with PD pathology. Studies here utilize PDE10i as a tool to further 
characterize the basal ganglia circuitry affected by PD pathology. 
 
The central hypothesis of this dissertation is that aggregated α-synuclein initiates an 
inflammatory cascade via activation of microglial cells and astrocytes that result in a 
feed-forward pathogenic mechanism. The feed-forward, dysregulated inflammatory 
cascade, in turn, results in de-differentiation of the astrocyte cells, causing further 
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propagation of pathophysiology. Ultimately, this process contributes to cell death, 
including the loss of dopaminergic cells in the substantia nigra (SN), which define PD. 
This results in an overall decrease of motor circuitry causing the symptoms of PD. 
Specifically, an increase in the activity of the indirect pathway leads to a decrease in 
thalamic drive to the motor cortex. Inhibition of PDE10A enzyme will preferentially 
activate the indirect pathway, with a relatively smaller activation of the direct pathway 
because of a differential inhibition of PDE10A in the medium spiny neurons (MSNs) 
(Figure 1). 
 
 
Figure 1: Central Hypothesis 
 
To test this hypothesis, the following objectives were defined: 
1. Determine the inflammatory effects of α-synuclein on microglia and 
astrocytes 
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2. Determine gene transcripts in proliferative astrocytes / radial glia and 
astrocyte precursor cells to understand genes and pathways that are important 
when astrocytes are proliferating and differentiating 
3. Determine genes associated with acetylated histones in proliferating 
astrocytes / radial glia and astrocyte precursor cells to understand one of the 
aspects of gene regulation associated with the proliferation and differentiation 
of astrocytes 
4. Determine acute PDE10i effects on neuronal activation in the brain to 
better understand activation within the motor cortex 
5. Determine the role of PDE10i in the D1 direct and D2 indirect pathway to 
better understand the overall decrease in motor cortex activation 
 
This set of objectives represents a unique exploration of the downstream effects of 
molecules abundantly expressed in the CNS, and the resulting dataset has helped define 
hypotheses for future therapeutic agents targeting α-synuclein and PDE10A. 
 
Organization 
This dissertation provides a literature review (Chapter 2) to orient the reader to the field 
of neuroinflammation and basal ganglia circuitry as it pertains to PD. Materials and 
methods used in this research are described in Chapter 3. Data acquired throughout this 
research are presented in the ensuing four chapters, each of which contains an 
independent introduction and discussion. Chapter 4 summarizes data describing the role 
of α-synuclein related effects in microglia and astrocytes, with emphasis on the context of 
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inflammation. Chapter 5 describes transcriptomic findings related to astrogenesis, while 
Chapter 6 describes histone acetylation modifications related to astrogenesis. Chapter 7 
summarizes the effects of PDE10i on neuronal activation within the neostriatum. Chapter 
8 articulates future directions based on the current work and how this data along with 
current literature is foundational for future experiments. 
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CHAPTER 2: LITERATURE REVIEW 
Parkinson’s Disease 
Parkinson’s disease (PD) is second only to Alzheimer’s disease as the most common 
neurodegenerative disease worldwide. Conservatively estimated, not accounting for the 
undiagnosed population, PD prevalence is approximately 0.3% of the general population 
in the United States (US). These rates decrease to 0.02% of people younger than 45 and 
increase to 1.2% of people older than 70, indicating that age is the major risk factor of 
PD. An estimated 630,000 people in the US have been diagnosed with PD in 2010, which 
is approximately 10% of the worldwide PD population. Projections that account for 
demographic changes and an aging population suggest that the US diagnosed patients 
will reach 819,000 by 2020, 1.06 million by 2030, 1.24 million by 2040, and 1.34 million 
by 2050, if no disease modifying treatment is found (Kowal et al, 2013). Therefore, it is 
critical to understand PD pathophysiology and thereby identify disease modifying 
therapeutic approaches. 
 
Pathology of Parkinson’s Disease: Dopamine Neuronal Cells, Inflammation and 
Lewy bodies 
A defining pathologic feature of PD is death of dopaminergic neurons in a basal ganglia 
nucleus termed the substantia nigra (Ehringer & Hornykiewicz, 1960; Hirsch et al, 1988). 
These neurons project to the neostriatum, which helps to regulate the voluntary 
movement via the extrapyramidal motor system (Figure 2, Young & Penney, 1984). The 
precise cause of cell death is unknown, however inflammation and protein clearance 
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deficits, such as proteosomal and lysosomal dysfunction, have been implicated (Zhou & 
Lim, 2009). 
 
 
Figure 2: Dopamine neurons in the substantia nigra project to the neostriatum 
Substantia nigra regions (purple) at the base of the brain contain cells that project 
nigrostriatal projections (black arrows) into the collective striatum regions (red), made up 
of the caudate nucleus and the putamen 
 
Imaging studies of PD patients using a positron emission tomography tracer, PK11195, 
have provided the evidence of activated resident immune cells throughout the basal 
ganglia including the SN (Bartels & Leenders, 2007; Gerhard et al, 2006). Further 
support for neuroinflammation associated with PD comes from post-mortem brain studies 
that have shown higher levels of neuroinflammatory cytokines associated with the 
presence of activated microglia in the SN (Brooks, 2005; Tansey & Goldberg, 2010). The 
current belief is that inflammatory processes during microglia polarization contribute to 
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the progression of PD through increased NFκβ activity and the apoptosis pathway 
(Gardet et al, 2010; Wang et al, 2015). 
 
Another hallmark feature of PD pathology is the presence of Lewy bodies and Lewy 
neurites, which are cellular inclusions with aggregated protein depositions, representing 
pathology in neuronal cell bodies and neuritic processes, respectively (Figure 3, 
Spillantini et al, 1998; Toulorge et al, 2016). 
 
 
Figure 3: Lewy body 
The black arrow points to a Lewy body (round dense inclusion) labeled with alpha-
synuclein immunohistochemistry (brown) and nuclear counterstain using hematoxylin 
(blue). 
 
The regional propagation pattern of Lewy bodies has been mapped and used by Braak et 
al. (Braak et al, 2003) to define 6 different, slowly progressing, pathological stages of 
PD. Lewy bodies may contain as many as 156 unique proteins (Leverenz et al, 2007), the 
most abundant being a protein termed alpha-synuclein (α-synuclein) which aggregates 
when misfolded. A deficit in protein clearance mechanisms is believed to underlie the 
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accumulation of misfolded proteins in Lewy bodies and Lewy neurites. Recent studies 
have uncovered a prion-like pathological mechanism of α-synuclein, which can be 
released, then taken up by nearby cells as a mechanism to propagate new Lewy body 
formation (Luk et al, 2012a; Luk et al, 2012b; Mougenot et al, 2012). 
 
Etiology and the Genetics of Parkinson’s Disease 
Idiopathic PD accounts for more than 90% of all PD cases (Gilgun-Sherki et al, 2004). A 
number of loci and specific gene mutations causing familial PD have been identified in 
recent years, which have begun to provide insights into the etiologic mechanisms of PD 
(reviewed by Cookson et al, 2008). On the other hand, the biologic mechanisms 
underlying idiopathic PD remain hypothetical. One hypothesis states aggregated protein 
deposition is toxic to neurons, while the other hypothesis proposes mitochondrial 
dysfunction and oxidative stress as the key neurodegeneration event (reviewed by Dauer 
& Przedborski, 2003). The major risk factor for idiopathic PD is age, but recent genome-
wide association studies (GWAS) have been shedding light on genetic risk factors. 
Polymorphic variants in the SNCA gene, that encodes for α-synuclein, are genetic risk 
factors of PD identified by multiple GWAS (Klein & Ziegler, 2011; Simon-Sanchez & 
Singleton, 2008). An interaction between genetic susceptibility and environmental 
factors, such as age and pesticide exposures, may explain the majority of idiopathic PD 
etiology (Gao & Hong, 2011). Interestingly, point mutations (A30P, E46K and A53T), 
duplications and triplication in the SNCA gene cause PD that has an earlier age of onset 
(Singleton et al, 2003). By and large, the mutated forms of α-synuclein aggregate at a 
higher rate (Taschenberger et al, 2012). The convergence of the presence of aggregated 
9 
 
α-synuclein in Lewy body pathology of PD and genetic etiology impinging on α-
synuclein mutations and polymorphisms has led to the tremendous focus on studying the 
physiological and pathological role of α-synuclein (Dexter & Jenner, 2013). 
 
Alpha-Synuclein 
The discovery of α-synuclein was made over 20 years ago, but its precise function still 
remains unknown (Jakes et al, 1994; reviewed by Ottolini et al, 2017). The human 
protein is a 140 amino acid heat-stable, soluble protein with an acidic C-terminal and 6 
repeats of KTKEGV on the N-terminus with an internal portion that is required for 
aggregation. It has a high affinity for lipids and associates with a variety of lipid 
membranes, including presynaptic vesicles and mitochondria (Galvagnion et al, 2015). 
Consistent with this binding, α-synuclein is implicated in regulating vesicle trafficking 
and soluble NSF attachment protein receptor (SNARE) complex assembly, as well as 
mitochondrial membrane/Complex I binding and inhibition (Ahmad et al, 2007; Fujita et 
al, 2012; Marques & Outeiro, 2012; Trojanowski & Lee, 2002). 
 
A number of post-translational modifications have been reported on various amino acids 
in the α-synuclein sequence and are thought to contribute to its aggregation (Barrett & 
Timothy Greenamyre, 2015). These include phosphorylation of serine at the 129 and 87 
amino acid sites, phosphorylation and nitration of tyrosine residues and sulfoxidation of 
n-terminal methionine. Also, oxidation of methionine prevents fibrillation and promotes 
formation of oligomers, which may contribute to the mechanism causing increased 
toxicity of the oligomers (Cole et al, 2005; Hokenson et al, 2004; Zhou et al, 2010a). 
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As mentioned above, α-synuclein is one of the most abundant proteins contained in Lewy 
bodies (Leverenz et al, 2007). In fact, in addition to PD, dementia with Lewy bodies and 
multiple system atrophy are neurodegenerative diseases defined by Lewy body pathology 
and are collectively termed synucleinopathies (Lim et al, 2016). The precise pathologic 
structure of α-synuclein that underlies PD remains a point of conjecture, but it has been 
proposed that soluble oligomeric forms of the protein may be more toxic than the large 
fibrillar, insoluble deposited forms (Kramer & Schulz-Schaeffer, 2007; Leverenz et al, 
2007). On the other hand, deposition of fibrillar α-synuclein may initiate 
neuroinflammation during clearance of the deposits by glial cells (Beraud et al, 2013). 
 
Various diverse and heterogeneous forms of α-synuclein could cause toxicity (Hashimoto 
et al, 2004; Lashuel et al, 2013; Luna & Luk, 2015). Oligomers and large aggregates 
could both be toxic to different types of cells in different conditions. Fibrils found in 
Lewy Bodies are typically 12–15 nm wide, however short proto-fibrils and spherical 
oligomers (ranging from 25-150 α-synuclein molecules) both containing β-sheet 
conformation, exist in Lewy Bodies (Conway et al, 2001; Norris et al, 2005)  
 
Large fibrils have been shown to be toxic. In culture, fibrillar α-synuclein exposure 
induced 1000-fold greater cell death than the oligomeric forms of α-synuclein (Pieri et al, 
2012). Also, α-synuclein fibrils have been shown to be toxic when binding to cell 
membranes reducing membrane integrity (Pieri et al, 2016; Shrivastava et al, 2015). On 
the other hand oligomers and short proto-fibrils have been shown to be toxic in vitro and 
in vivo altering membrane permeability and increasing of calcium influx, triggering cell 
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death of dopamine neurons (Campioni et al, 2010; Conway et al, 2000; Winner et al, 
2011). Data have shown that oligomers cause toxicity by damaging lysosomal 
membranes, mitochondrial membranes while increasing oxidative stress (Hsu et al, 
2000), or disrupting microtubule transport (Alim et al, 2004) or axonal transport of 
synaptic proteins leading to a dysfunctional synapse (Scott et al, 2010). Also, oligomers 
are thought of as intermediates on the pathway from monomer to fibril, however “off-
pathway” oligomers have been discovered to be trapped, unable to form fibrils or degrade 
to monomers (Chen et al, 2015; Lorenzen et al, 2014). It is also possible that 
concentrations of intermediates increase as fibrils aggregate in cells, which increases the 
oligomeric-mediated toxicity (Cremades et al, 2012). 
 
Pathophysiology of Parkinson’s Disease: Neuroinflammation and Glial Cells 
As stated above, neuroinflammation is a key feature of PD. There are two types of cells 
that play a critical role in regulating neuroinflammation: microglia and astrocytes. 
Microglia, 10% of all glial cells, normally function in synaptic pruning, scavenging for 
intruders or cleaning up neuronal cell debris (Sanchez-Guajardo et al, 2013b). However, 
during the progression of PD, local microglia will respond to α-synuclein aggregation, 
neuronal cell death, presence of reactive oxygen species and presence of cytokines, such 
as tumor necrosis factor-alpha (TNFα) and interleukin-1 beta (IL-1β) (Tansey & 
Goldberg, 2010). The response of the local microglia may include the release of anti-
inflammatory as well as pro-inflammatory cytokines, which in turn affect nearby cells 
such as the astrocytes and neurons (Bruck et al, 2016). 
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In PD brains, microglia and astrocytes come into contact with α-synuclein (Shrivastava et 
al, 2016). A number of studies have been carried out to understand α-synuclein-
dependent regulation of glial cell functions. For example, neuron-released, oligomeric α-
synuclein has been shown to activate microglial cells through Toll-like receptor 2 (TLR2) 
(Kim et al, 2013). Transgenic mice over-expressing α-synuclein can form aggregates in 
vivo, and when injected with lipopolysaccharide (LPS), there is a synergistic pathologic 
effect of inflammation, possibly through the LPS inflammatory action on microglia and 
subsequent TLR2 up-regulation in vivo (Laflamme et al, 2001). This demonstrates a 
prominent role of α-synuclein aggregation and inflammation in pathogenesis of PD (Gao 
et al, 2008). However, the current literature has not systematically studied the 
concentration response or time course of inflammation inducing effects of monomeric 
and aggregated α-synuclein. There is also paucity of data characterizing α-synuclein 
effects on microglia and investigating whether these cells could act synergistically to 
enhance neuroinflammation-mediated toxicity. 
 
Astrocytes and Proliferative Reactive Gliosis 
Astrocytes, like microglia, have a multitude of roles in the developing nervous system 
and are becoming increasingly more important as a factor underlying many diseases 
when these roles are impaired. They can act as neural stem cells within subpopulations of 
brain regions during development, regulate cerebral blood flow at the vascular interface, 
store glycogen, transport water, take in extracellular potassium during intense synaptic 
functions and regulate synapses by the uptake of excess extracellular neurotransmitters 
(Halassa et al, 2007; Rossi & Volterra, 2009). Astrocytes are the most abundant glial cell 
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in the adult mammalian brain. Recent analysis of astrogenesis indicates that these cells 
are primarily generated in the postnatal rodent central nervous system (CNS, Bandeira et 
al, 2009). The most common contributing sources of astrocyte production are radial glial 
cells, which transform into astrocyte progenitors cells, and proliferating sub-ventricular 
zone astrocyte progenitors (Ge et al, 2012; Magavi et al, 2012). Neuron-glial antigen 2 
(NG2)-positive glia provide ventral brain regions with a small percentage of astrocytes 
(Guo et al, 2009; Zhu et al, 2008). Astrocyte progenitor cells contribute small numbers of 
astrocytes during the first postnatal day (P0-P1), however these cells proliferate 6 to 8 
fold by the end of the first postnatal week (P7-P8, Ge et al, 2012). A large portion of 
astrocytes are produced during these stages, although these cells continue to locally 
generate the remainder of astrocytes in the adult brain (Ge & Jia, 2016). 
 
Radial glial cells retain their cell bodies in the ventricular zone, where they 
asymmetrically divide (Yamaguchi et al, 2016). Cell division gives rise to a radial glial 
cell and a progenitor cell, which will migrate into the outer layers and mature or 
proliferate further. Basic helix-loop-helix transcription factors play roles in fate 
determination of the progenitor cells, which express Hes1 during the astrogenesis stages 
(Imayoshi & Kageyama, 2014). Radial glial cells share many properties with astrocytes 
including expression of extracellular proteins, namely GLAST (Gotz et al, 2015). 
GLAST (Glutamate Aspartate Transporter) is expressed on the cell surface of a large 
majority of early postnatal transforming radial glia and astrocytes in the brain and spinal 
cord (Chaudhry et al, 1995; Jungblut et al, 2012; Lehre et al, 1995; Shibata et al, 1997; 
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Zhou et al, 2006), which makes it an excellent candidate marker to utilize when acutely 
isolating these cells from brain (Jungblut et al, 2012).  
 
In most central nervous system (CNS) diseases or injuries, astrocytes enter a state termed 
reactive gliosis, in which astrocytes become hypertrophic, stop performing their 
supportive functions, de-differentiate and in some cases proliferate (de Chevigny et al, 
2008; Yu et al, 2006). In moderate to severe cases of gliosis, astrocytes have been shown 
to secrete molecules such as TNFα and IL-1β, which activate microglia (Medeiros & 
LaFerla, 2013). The role of astrocytes in PD is not well understood. One hypothesis 
proposes that astrocytes, as a result of cellular stress, release cytokines, which regulate 
peripheral immune cells, resulting in a feed-forward mechanism, maintaining 
neuroinflammation and contributing to PD progression (Sanchez-Guajardo et al, 2013b). 
 
Regardless of specific disease pathologies, reactive glia appear to undergo de-
differentiation, leading to a loss of function. If the inflammatory state continues 
unchecked for long periods of time, the astrocytes (along with other cells) will coalesce 
to form a permanent barrier referred to as a glial scar. While it is appreciated that the cells 
undergo de-differentiation it is not understood whether reactive gliosis is representative 
of a particular stage of development brought about by mediators of inflammation. It is 
also not clear whether signaling pathways labeled “inflammatory” might also play normal 
roles in the differentiation of astrocytes (Vazquez-Chona et al, 2011). Many studies have 
made attempts at this goal by in vitro expansion of astrocytes in cellular conditions that 
may promote artificial cell qualities (Beckervordersandforth et al, 2010; Sirko et al, 2015; 
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Zamanian et al, 2012; Zhang et al, 2016b) One should use caution when interpreting 
these results, since these reports may be an incomplete characterization of the state of 
cells in vivo. Furthermore, experiments should be completed using cells from in vivo 
progenitor populations comparing them with mature populations from the brain to better 
define signaling pathways important in the differentiation of astrocytes. More recent 
attempts have isolated cells using green fluorescent protein overexpressed in astrocytes, 
again potentially introducing artificial qualities in the cells (Cahoy et al, 2008). 
 
Within these experiments viable comparisons can be made between progenitor cells and 
mature astrocytes since these cell types share functions in homeostasis and 
gliotransmission. However, differences in gene expression would be expected because of 
major functional differences. The key difference is that differentiated parenchymal 
astrocytes do not divide in healthy brain, while an astrocyte/radial glial cell acting as a 
neural progenitor cell divides at a constant yet low frequency (Robel et al, 2011). 
Emerging technologies for single cell isolation and whole genome sequencing will 
benefit this research field. 
 
Symptoms of Parkinson’s Disease and Parkinsonism 
The cardinal motor symptoms of PD are bradykinesia, rigidity, and resting tremor (Figure 
4). These symptoms together form what is known as parkinsonism. It is noteworthy that 
the basal ganglia system requires the loss of 70% of dopamine neurons in the SN before 
the emergence of the parkinsonism movement disorder (Damier et al, 1999). In earlier 
stages of the disease (Braak stages 1 and 2), patients predominantly experience symptoms 
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such as loss of smell and REM sleep disorders that correlates with Lewy pathology in the 
olfactory nuclei and brain stem, respectively (Halliday & McCann, 2010; Hindle, 2010). 
Parkinsonism occurs in Braak stages 2 and 3. With further disease progression, patients 
experience cognitive problems and dementia, consistent with Lewy body pathology in the 
neocortex (Ding et al, 2015). 
 
 
Figure 4: Characteristic PD patient 
Sketch by Sir William Gowers in 1886 represents a typical PD patient including 
illustration of a profile and direct facing image view of bradykinesia, asymmetric tremor 
and rigidity. 
 
Current Treatments of Symptoms of Parkinson’s Disease 
The currently marketed treatments of PD consist of drugs and procedures that only 
modify the symptomatic problems of the movement disorder described above, not the 
underlying pathology. The basis of the treatment is founded on augmenting dopaminergic 
neurotransmission in the basal ganglia via one of the following mechanisms: boosting 
dopamine synthesis via a precursor of dopamine, Levodopa (L-DOPA), activation of 
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dopamine D2 receptors, or inhibition of dopamine metabolizing enzymes, monoamine 
oxidase B (MAO-B) or catechol-O-methyl transferase (COMT). However, these drugs 
lose their efficacy or produce intolerable side effects with continued use and disease 
progression. In severe and refractory cases, deep brain stimulation (DBS) of the basal 
ganglia nuclei is prescribed to normalize the motor output (Yuan et al, 2010). 
 
Extrapyramidal Basal Ganglia Neuronal Pathways 
Dopamine neurons within the SN have a prominent role in regulation of the basal ganglia 
motor output. When the dopamine neurons in the SN depolarize, they release dopamine 
into the neostriatal synaptic cleft where it activates the D1 or D2 family of G-protein 
coupled receptors (GPCR) present on the postsynaptic cells. These postsynaptic cells are 
termed medium spiny neurons (MSNs) which express the inhibitory neurotransmitter, γ-
aminobutyric acid (GABA). Morphological and functional studies have identified two 
distinct MSN pathways termed the so-called direct and indirect pathways (Gerfen, 1992). 
The MSNs in the direct pathway selectively express the Gαs-coupled D1 receptor. 
Activation of D1 receptors by dopamine will stimulate cyclic adenosine monophosphate 
(cAMP) production by adenylyl cyclase and increase basal ganglia output. The MSNs in 
the indirect pathway express the Gαi-coupled D2 receptor that inhibits cAMP production 
(Perreault et al, 2011). The activation of D2 receptors in the indirect pathway inhibits 
cAMP activity and thereby augments basal ganglia motor output. Thus, dopamine is 
overall stimulatory for the extrapyramidal motor system. In PD, the loss of SN dopamine 
neurons leads to disinhibition of the indirect pathway, which results in the decrease in 
basal ganglia extrapyramidal neuronal output, resulting in bradykinesia. Replacement of 
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dopamine via L-DOPA or direct activation of the D2 receptor on the indirect pathway 
provides symptomatic relief in PD patients. On the other hand, D2 receptor antagonists 
such as antipsychotic medications cause parkinsonism symptoms. As mentioned above, 
these drugs lose their efficacy over time or produce adverse events. Therefore, there is a 
continued need to identify additional mechanism and novel therapies that regulate basal 
ganglia activity.  
 
PDE10 Enzymes and Cellular Pathways 
Phosphodiesterase (PDE) enzymes cleave cyclic nucleotides and thereby regulate second 
messenger signaling casacades. PDE10A, like several other PDEs, cleaves both cAMP 
and cyclic guanosine monophosphate (cGMP) to AMP and GMP, respectively. PDE10A 
is of particular relevance to the basal ganglia because it is expressed selectively in the 
MSNs of the neostriatum in both the D1- and D2-containing neurons (Kleiman et al, 
2011). 
 
Studies have identified MP-10 to be a potent PDE10A small molecule inhibitor both in 
vitro and in vivo, which increases cAMP/cGMP intracellular concentrations, in turn 
augmenting D1 agonist and D2 antagonist-mediated effects (Bollen & Prickaerts, 2012; 
Grauer et al, 2009; Schmidt et al, 2008). PDE10i have been proposed as therapeutics for 
schizophrenia, since current marketed treatments consist of dopamine D2 receptor 
blockers (Siuciak, 2008), along with other treatments including weak antagonists of 
NMDA-type glutamate receptors to offset secondary effects of disinhibition of the 
subthalamic nucleus and glutamatergic overstimulation of the internal globus pallidus and 
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SN (Hallett & Standaert, 2004). In order to determine whether PDE10 inhibition may 
have a liability to induce parkinsonism (Niccolini et al, 2015), it is important to determine 
relative effects of MP-10 in direct or indirect pathways. Furthermore, MP-10 is a good 
tool to characterize the basal ganglia circuitry within the context of PD pathophysiology. 
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CHAPTER 3: MATERIALS AND METHODS 
Animal Care and Use 
All animal experiments were carried out in accordance with the Declaration of Helsinki 
and the Guide for the Care and Use of Laboratory Animals by the U.S. National Institute 
of Health and the EU Directive 86/609/EEC. 
 
Preparation of α-synuclein monomer and fibrils for in vitro assessment 
Lyophilized α-synuclein (R-Peptide, Bogart, GA) was resuspended to 1 mg/mL (in 10 
mM Tris-HCl, pH 7.4). The amount of endotoxin was found to be <1 endotoxin unit/mg 
of protein. The unagitated solution was aliquoted and stored at -20
o
 C. To prepare fibrillar 
α-synuclein, NaN3 was added at a final concentration of 0.02% and the solution was 
agitated at 1400 revolutions per minute (RPM) at 37
o
 C for 7 days on an Eppendorf 
Thermoshaker. Agitated solution was dialyzed against phosphate buffered saline (PBS), 
pH 7.4 to remove NaN3 and to enrich for fibrillar α-synuclein using 20K molecular 
weight cut-off (MWCO) Slide-A-Lyzer dialysis device (Thermo, Rockford, IL). Fibrillar 
α-synuclein was aliquoted and stored at -20o C. Sister aliquots of the same lot of 
monomeric and fibrillar α-synuclein was used for all studies described. 
 
Characterization of α-synuclein fibrils by thioflavin-T binding assay 
A 10 μL aliquot of agitated and unagitated α-synuclein solutions were mixed separately 
with 10 μL each of thioflavin-T (120 μM in 100 mM NaPO4, pH 7.4) and directly added 
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to a black 384 well plate (Thermo Scientific, Rockford, IL) to assess fibril formation by 
measuring emission at 494 nm. 
 
Characterization of α-synuclein fibrils by Western Blotting 
Monomer and fibril concentrations were determined by the Bicinchoninic Acid (BCA) 
assay (Thermo Scientific, Rockford, IL). Five μg of each solution were denatured at 95oC 
for 5 minutes and separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). The proteins were blotted onto polyvinylidene difluoride 
(PVDF) membrane and blocked with 5% non-fat milk for 16 hours at 4
o
 C. An overnight 
incubation with 1 μg/mL of anti-α-synuclein (Clone 42, BD Biosciences, San Jose, CA) 
in 5% non-fat milk was followed by 3 rinses with Tris-buffered saline with 0.05% 
Tween-20 (TBST). Membranes were incubated with the horseradish peroxidase-
conjugated secondary goat anti-mouse antibodies (Cell Signaling, Danvers, MA) for 1 
hour at room temperature, then rinsed with TBST and developed for chemiluminescent 
image acquisition on the ImageQuant LAS 4000 biomolecular imager (GE, Uppsala, 
Sweden). 
 
Characterization of α-synuclein fibrils by transmission electron microscopy 
Agitated protein was prepared for transmission electron microscopy (TEM) evaluation 
and visualization as previously described (Guo & Lee, 2011). Briefly, 5 μL of undiluted 
α-synuclein fibrillar preparation was placed on a meshed formvar/carbon coated copper 
grid for 3 minutes. The protein was rinsed in 50 nM Tris-HCl buffer, pH 7.5, for 5 
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minutes and negatively stained with 20 drops of 2% aqueous uranyl acetate in 0.5% 
glacial acetic acid. The specimens were air-dried for 1 hour prior to visualization with a 
Philips CM-100 TEM at 80 kV. Digital images were collected using Gatan Digital 
Micrograph software. 
 
BV-2 cell and primary microglia cultures and treatment 
BV-2 cells are a transformed microglia cell line (Blasi et al, 1990). BV-2 cells were 
seeded in a 150 cm
2
 flask (Corning, Tewksbury, MA) at 1 x 10
6
 cells and cultured in 30 
mL of Dulbecco’s Modified Eagle’s Medium (DMEM; HyClone, Logan, UT) 
supplemented with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY) 
in a humidified 5% CO2 incubator at 37
o
 C for 72 hours. Cells were washed once with 
Hank’s balanced salt solution (HBSS; HyClone, Logan, UT), then dissociated from the 
flask using TrypLE Express Enzyme (Life Technologies, Grand Island, NY) and 
resuspended in DMEM (HyClone, Logan, UT) supplemented with 10% FBS (Life 
Technologies, Grand Island, NY) prior to plating on poly-D-lysine (PDL)-coated plates 
(Corning, Tewksbury, MA). For RNA analysis by quantitative reverse-transcription-
polymerase chain reaction (RT-qPCR), cytokine protein assessment by enzyme-linked 
immunosorbent assay (ELISA) and imaging studies, BV-2 cells were plated in 96-well 
plates at 1.5 x 10
4
 cells while the primary microglia were plated in 96-well plates at 4 x 
10
4
. For phagocytosis studies, BV-2 cells were plated at 1 x 10
5
 cells/well in 12-well 
plates. These cell densities reflect experimental optimization through pilot studies. After 
24 hours, media was replaced with fresh DMEM (HyClone, Logan, UT) without serum. 
LPS from E. coli (strain 0111:B4, Sigma-Aldrich, St. Louis, MO) was diluted to 100 
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ng/mL and used as control treatments in indicated experiments. Other treatments and 
durations are indicated in individual figure legends. 
 
Cytotoxicity Assessment 
Following treatment as indicated in figure legends, supernatant media from individual 
wells were directly tested for presence of lactate dehydrogenase (LDH) using a 
cytotoxicity detection kit (Roche, Indianapolis, IN). 100 μL of supernatant was added to a 
clear polystyrene 96 well plate (Corning, Tewksbury, MA) prior to incubation with 100 
μL of freshly prepared 1:45 ratio mixture of diaphorase / NAD+ and iodotetrazolium 
chloride / sodium lactate (Roche, Indianapolis, IN) for 30 minutes in the dark at room 
temperature. After incubation, the absorbance of each sample was measured at 490 nm 
using a SpectroMax M5 Microplate Reader (Molecular Devices, Sunnyvale, CA). 
 
RT-qPCR analysis of BV-2 microglial cells 
Total RNA was extracted from BV-2 microglial cells using TRIzol reagent (Life 
Technologies, Grand Island, NY) followed by reverse transcription using the High 
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). All cDNAs were 
assayed for genes of interest using TaqMan Gene Expression Analysis (Applied 
Biosystems, Foster City, CA) and the Assay-On-Demand primer/probe sets including Il6 
(Mm00446190_m1), Tnf (Mm00443258_m1), Nos2 (Mm00440502_m1), Arg1 
(Mm00475988_m1), Il10 (Mm01288386_m1), Chil3 (Mm00657889_mH), Mrc1 
(Mm01329362_m1), Trem2 (Mm04209424_g1), Tyrobp (Mm00449152_m1), Cd33 
24 
 
(Mm00491152_m1) and Gapdh (Mm99999915_g1). Triplicate samples were subjected to 
qPCR using ABI 7900HT real-time PCR system (Applied Biosystems, Foster City, CA) 
with the maximum cycle number of 40. Relative gene of interest mRNA levels were 
quantitated by determining the cycle number at which amplification detection threshold 
was achieved followed by normalization to that of the housekeeping gene, 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh). 
 
Immunocytochemistry and image analysis of BV-2 microglial cells 
Following treatment of BV-2 microglial cells for 3 and 24 hours, media was replaced 
with 50 μL of 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 20 
minutes. The cells were washed with PBS and permeabilized for 10 minutes with 50 μL 
of PBST, containing 0.05% Tween 20 (Life Technologies, Grand Island, NY) followed 
by 3 washes with PBS. Blocking was done with 1% bovine serum albumin (BSA; Life 
Technologies, Grand Island, NY) diluted in PBS for 24 hours at 4
o
 C. To assess pro-
inflammatory phenotype, cells were incubated with a rabbit antibody to ionized calcium 
binding adaptor molecule 1 (IBA1) at 1 μg/mL in 1% BSA (Wako Chemicals, Richmond, 
VA) for 24 hours at 4
o
 C. This was followed by incubation with 2 μg/mL of Alexa-fluor 
555 labeled goat anti-rabbit IgG secondary antibodies (Life Technologies, Grand Island, 
NY) for 60 minutes, 3 washes in PBS and addition of 10 μg/mL Hoechst 33342 (Life 
technologies, Grand Island, NY) for 2 minutes to label cell nuclei. High content images 
were generated using the Cellomics Arrayscan VTI HCS Reader (Thermo Fisher 
Scientific, Pittsburgh, PA) and the default software was used to compute mean number of 
cell bodies, total signal intensity and mean cell body area. 
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Cytokine level detection in BV-2 microglial cells and primary microglia 
Meso Scale Discovery (MSD, Gaithersburg, MD) platform was used for assessment of 
cytokine levels per the manufacturer’s instructions. Briefly, supernatant media from each 
treatment well were diluted 2 fold with Diluent 41 and 50 μL of each sample was 
analyzed on the Proinflammatory Panel 1 (mouse) Plate. Plates were shaken at 600 RPM 
for 2 hours at room temperature. After 3 washes with 150 μL of 1X Wash Buffer, 25 μL 
of solution containing detection antibodies for 10 different cytokines (Meso Scale 
Discovery, Gaithersburg, MD) was added to each well followed by shaking at 600 RPM 
for 2 hours at room temperature. Following 3 washes with 150 μL of 1X Wash Buffer, 
150 μL of Read Buffer T was added to each well prior to analyzing with Sector Imager 
6000 (Meso Scale Discovery, Gaithersburg, MD). All samples were interpolated using 
individual standard curves for each of the cytokines and reported at pg/mL. 
 
Phagocytosis detection in BV-2 microglial cells and primary microglia 
BV-2 microglial cell lines or primary microglia were treated as specified in the figure 
legends. 1 mL (for BV-2 cells) or 100 uL (for primary cells) of 0.1 mg/mL pHrodo green 
conjugated E. coli BioParticles (Life Technologies, Grand Island, NY) were added to 
each sample well in a humidified 5% CO2 incubator at 37
o 
C for 1 hour. After aspirating 
the particles, cells were washed with ice cold Live Cell Imaging Solution (Life 
Technologies, Grand Island, NY) and then completely dissociated from the plate by a 3-
minute trypsinization process using TrypLE Express Enzyme (Life Technologies, Grand 
Island, NY). Each sample was washed individually in 1% BSA (Life Technologies, 
Grand Island, NY) diluted in PBS. Each sample was analyzed on a Guava easyCyte flow 
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cytometer (EMD Millipore, Billerica, MA) by collecting 10,000 events per sample. 
Events were gated based on forward and side scatter plots. Positive thresholds were based 
on the background level of samples without BioParticles and were used consistently to 
determine % of cells with positive green fluorescence of each sample. Data are shown as 
percent of positive cells for each treatment condition normalized to the control signal in 
samples treated with serum-free media. The data represent average values from multiple 
independent experiments. 
 
Isolation of GLAST (+) cells 
Timed pregnant C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were housed at 
the Indiana University Purdue University Indianapolis Science Animal Resource Center 
and maintained at a 12 hour light/dark cycle. Whole brains from 4 separate litters with an 
average of 6 mice per liter for were used for both P0 and P8 isolations.  Each litter was 
considered a single sample and brains from a litter were pooled and dissected in ice cold 
1X HBSS. Four separate pooled samples were analyzed by RNA-seq for each 
developmental stage. Brains were enzymatically dissociated by incubating brain pieces 
with trypsin using the Neural Tissue Dissociation Kit (Miltenyi Biotec, Auburn CA) and 
the automated gentleMACS Dissociator (Miltenyi Biotec, Auburn CA) operating on 
default settings.  Briefly, tissue was dissociated for 37 seconds in pre-heated enzyme mix 
1 (Miltenyi Biotec, Auburn CA) before incubating at 37⁰ C for 15 minutes with rotation 
(12 rpm) using the MACSmix Tube Rotator (Miltenyi Biotec, Auburn CA). Following 
incubation with trypsin, 20 μL of Solution 3 and 10 μL of Solution 4 from the trypsin 
enzyme mix 2 (Miltenyi Biotec, Auburn CA) were added per P8 brain or per P0 brains. 
27 
 
Tissue was further incubated at 37⁰ C for 10 minutes with rotation (12 rpm) using the 
MACSmix Tube Rotator, mechanically dissociated for 61 seconds, and then incubated 
again at 37⁰C for 10 minutes with rotation (12 rpm) to complete the dissociation. The 
single cell preparations were applied to a 30 μm cell strainer and resuspended in 500 μL 
0.5% Bovine Serum Albumin (BSA) in 1X PBS. Cells were labeled using the Anti-
GLAST (ASCA-1) MicroBead Kit and magnetically separated into 1 mL volume through 
MACS separation columns after washing the column three times with 500 μL of 0.5% 
BSA in 1X PBS (Miltenyi Biotec, Auburn CA). 
 
Immunofluorescence and image analysis of developing mouse brain sections 
Whole brains from embryonic day 16.5 (E16.5), P0, P8 and P14 mice were dissected in 
ice cold 1X Hank’s Balanced Salt Solution (HBSS, Sigma, St. Louis, MO) and fixed in 
4% paraformaldehyde in 0.1M phosphate buffer, pH 7.4 overnight. The tissue was 
cryoprotected in overnight incubations of several graded sucrose solutions (5%, 10%, 
15% and 20%) made in 0.1M phosphate buffer, pH 7.4. The tissue was frozen in a 3:1 
solution of 20% sucrose/optimal cutting temperature (OCT) and stored at -80° C. Twelve 
micron thick sections were cut using a Leica CM3050 S cryostat and placed on 
Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) treated with Vectabond (Vector 
Labs, Burlingame, CA), and were stored at -80° C until use. Prior to immunolabeling, 
sections were warmed to room temperature for 20 minutes, post-fixed with 4% 
paraformaldehyde for 30 minutes and rinsed in 1X PBS twice for 2 minutes each. To 
reduce the autofluorescence, sections were treated with 1% sodium borohydride (Acros 
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Organics, Belgium) in 1X PBS for 2 minutes at room temperature. Tissue was blocked 
with 10% goat serum in 1X PBS containing 0.25% Triton X-100 (Bio-Rad, Hercules, 
CA) at room temperature for 1 hour. Sections were incubated with primary antibodies, 
diluted in 0.025% Triton X-100 in 1X PBS with 2% goat serum, overnight at 4° C (Table 
1). 
 
Table 1: Antibodies used for fluorescent immunohistochemistry colocalization studies on 
different stages of mouse brain sections. 
 
 
Sections were rinsed in 1X PBS twice for 10 minutes each, then incubated with Dylight 
488 and 594 conjugated secondary goat antibodies (Jackson Immunoresearch, West 
Grove, PA) at 1:800 each in 1X PBS for 1 hour at room temperature. Sections were 
incubated with a 0.2% Hoechst 33342 (Invitrogen, Grand Island, NY) solution in 1X PBS 
for 5 minutes, rinsed twice with 1X PBS for 10 minutes each, and mounted with Aqua 
Poly/mount (Polysciences, Inc., Valley Road Warrington). For double-labeling of slides 
from the same species, one antigen was labeled with TSA™ Plus Fluorescein System 
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(PerkinElmer, Akron, Ohio) as per manufacturer’s instructions while the second antigen 
was immunolabeled as indicated above. 
 
Olympus Fluoview FV 1000 confocal microscope was used to acquire images of mid-
sagittal forebrain, olfactory bulb and cerebellum from E16, P0, P8 and P14 brains. 
Confocal image files were imported into the FIJI distribution of ImageJ for analysis 
(Schindelin et al, 2012; Schneider et al, 2012). Analyses of all images were completed 
using an adapted version of an ImageJ macro that was designed to compute areas of 
overlap and colocalization (Zinchuk et al, 2007). The degree of overlap was totaled for 
each image and normalized by scaling the images to the same number of pixels sampled. 
 
FACS analysis of GLAST (+) cells 
Subsets of magnetically positive and negative cells were incubated with 1μg/mL of 
Phycoerythrin (PE) directly labeled anti-GLAST (ASCA-1) or mouse IgG antibodies 
diluted in 0.5% BSA in 1X PBS at 4° C for 30 min. Cells were washed with 0.5% BSA in 
1X PBS and a minimum of 10,000 live cells per sample were analyzed using the 
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). The intensity of 
fluorescent signal of anti-GLAST stained samples were compared to IgG negative 
controls and percent positive signal was calculated. 
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RNA extraction and isolation from GLAST (+) cells 
RNA was prepared using the PicoPure RNA isolation kit (Applied Biosystems, Foster 
City, CA). GLAST positive cells were incubated in 100μL of extraction buffer for 30 
minutes at 42
 o
 C. The supernatant was mixed with equal volume of 70% ethanol. The 
RNA purification column was preconditioned with 250μL of conditioning buffer prior to 
adding the RNA extract mixture, followed by 3 washing steps and DNase treatment. 
Eleven microliters of eluted RNA was tested in RNA integrity assays prior to preparation 
of library for sequencing. 
 
RT-qPCR of genes from GLAST (+) cells 
Total RNAs from isolated cells were reverse transcribed using the TaqMan Reverse 
Transcription Reagents (N8080234, Fisher Scientific, Pittsburgh, PA). cDNAs were 
assayed for genes of interest using TaqMan Gene Expression Analysis (Applied 
Biosystems, Foster City, CA) and the Assay-On-Demand primer/probe set (Table 2). 
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Table 2: qPCR primers used to validate RNA-seq analysis. 
 
 
Gene of interest mRNA levels were quantitated by determining the cycle number at 
which amplification detection threshold was achieved. Real time-PCR reactions were 
performed in 10 µl reactions. Triplicate samples were subjected to quantitative PCR 
using QuantStudio 7 Flex Real-Time PCR System with the maximum cycle number of 
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50. After normalization to the housekeeping gene, Gapdh, the relative expression of the 
gene of interest was reported. 
 
QC and Preparation of library for RNA-seq 
Initial isolated RNA concentration was determined using the Qubit 2.0 Fluorometer and 
RNA High Sensitivity Assay (Life Technologies Corp., Carlsbad, CA). Total RNA 
integrity was assessed using the Agilent 2100 Bioanalyzer along with the RNA 6000 Pico 
Kit (Agilent Technologies, Santa Clara, CA). All samples had an RNA Integrity Number 
(RIN) value greater than or equal to 7.9. A RIN value of 7 or above on a scale of 10 is 
considered high integrity based on the limit of detection of a fluorescence peak of the 28S 
rRNA (Schroeder et al, 2006). Libraries were constructed using the TruSeq RNA Sample 
Preparation Kit v2 set A and protocol companion (Illumina Inc., San Diego, CA). Briefly, 
poly-A containing mRNA was purified from 60 ng total RNA using poly-T oligo-
attached magnetic beads, then heat fragmented at 94° C for 4 minutes. First strand cDNA 
was synthesized using reverse transcriptase and random hexamers, followed by second 
strand synthesis. The ends of the double stranded cDNA were polished and 3’ adenylated, 
then ligated with indexing adapters to prepare them for hybridization on the flowcell. The 
library was then PCR amplified to enrich for properly ligated fragments and purified 
using AMPure XP beads (Beckman Coulter, Inc.). Final library integrity and size 
distribution was assessed using the Agilent Bioanalyzer 2100 along with the DNA 7500 
Assay (Agilent Technologies, Santa Clara, CA). The Qubit 2.0 Fluorometer along with 
the High Sensitivity DNA Assay (Life Technologies Corp.) was used to determine final 
library concentration.  Libraries were normalized to 10 nM in buffer EB (Qiagen, Santa 
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Clarita, CA) and combined together for multiplexing. Sequencing was conducted on one 
lane of Illumina HiSeq2000 (BGI International) using 100bp paired-end reads. An 
average of 25 million paired-end reads was obtained per sample. 
 
Bioinformatics and Statistical Analysis of RNA-seq 
Reads were analyzed with quality recalibration software (Illumina Inc., San Diego, CA) 
for each sequence read. A 5-base sliding window was used when assigning quality scores 
(Q-scores). To eliminate low-quality reads while retaining high-quality regions, a 
position with an average Q-score of less than 20 was truncated and any read length less 
than 35 bases was discarded (Breese & Liu, 2013; Juan et al, 2013; Todd et al, 2013). 
Sequence reads were aligned to the mouse genome (mm9) using TopHat (Trapnell et al, 
2009). After aligning the sequence reads to a filtering index, including ribosomal RNAs 
and other repeat sequences of no interest, three levels of sequence alignment was 
conducted: genome, known junctions (Waterston et al, 2002) and novel junctions based 
on enriched regions identified during genomic alignment. Uniquely aligned sequences 
with no more than two mismatches were allowed. Fragments per kilobase of transcript 
per million (FPKM) was calculated based on the number of reads aligned to a gene. 
Differential expression between P0 and P8 cells was determined using EdgeR with 
continuous dispersion (Robinson et al, 2010). False Discovery Rate (FDR) was calculated 
according to Benjamini and Hochberg (Benjamini & Hochberg, 1995). 
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Transcription Factor Network Analysis of RNA-seq data set 
A representative list of 500 of the most highly expressed transcripts from P0 or P8 
cells based on FPKM were investigated further through network analysis using MetaCore 
(GeneGo Inc., St. Joseph, MI). The transcription factor network analysis algorithm 
(version 6.24 build 67895) was applied to identify subsets of genes with coordinate 
regulation by known transcription factors. Transcription factors were reported based on 
hypergeometric distribution and ranked according to p-value. 
 
Chromatin Immunoprecipitation from GLAST (+) cells 
GLAST positive cells were fixed in freshly prepared 1% formaldehyde solution for 15 
minutes, rocking at room temperature. Fixation was stopped with 2.5 M glycine solution 
for 5 minutes at room temperature. Cells were pelleted and washed once in 10 mL of 
chilled 0.5% Igepal CA-630 in 1X PBS and resuspended in 10 mL of chilled 0.5% Igepal 
CA-630 in 1X PBS with 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells were 
pelleted immediately and supernatant was completely removed before snap-freezing in 
liquid nitrogen. Chromatin immunoprecipitation (ChIP) was carried out as detailed 
previously (Labhart et al, 2005). Briefly, chromatin was extracted from frozen samples 
by adding lysis buffer and processing with a Dounce homogenizer. Lysates were briefly 
sonicated to shear the DNA. Input control samples were purified from an aliquot of the 
P0 and P8 chromatin at this stage of processing and quantified using a Nanodrop 
spectrophotometer (ThermoScientific, Philadelphia PA), while the rest of the samples 
underwent ChIP. ChIP was performed using an anti-acetylated histone 3 lysine 9 
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antibody (acH3K9, clone 1B10, Active Motif, Carlsbad, CA). An aliquot of P0 or P8 
genomic DNA was precleared with protein G-coupled agarose beads (Invitrogen, Grand 
Island NY), incubated overnight with anti-acH3K9 antibody, washed, and incubated with 
protein G–coupled agarose beads. Complexes containing DNA, acetylated histone 3 
lysine 9 and antibody were precipitated, washed and eluted from the beads with SDS-
containing buffer. DNA/protein complexes were treated with RNAse and proteinase K 
solution and crosslinks reversed by incubating overnight at 65⁰ C. Immunoprecipitated 
DNA was purified by phenol-chloroform extraction and ethanol precipitated. 
Immunoprecipitated DNA was prepared for sequencing by PCR amplification. The ends 
of the sheared DNA samples were polished and 5’-phosphorylated by incubating with a 
mixture of Klenow fragment, T4 polynucleotide kinase and T4 DNA polymerase 
followed by addition of a 3’-A to DNA ends using the Klenow fragment, and Illumina 
adaptors were ligated to the 3’ ends. Following addition of adaptors the resulting 
fragments were size-fractionated on a 2% agarose gel, and fragments between 180-250bp 
in length were purified and amplified for 18 cycles by PCR. Following quantitation, the 
libraries were sequenced using the Illumina Hi-Seq Next-Gen sequencing platform 
(Illumina Inc., San Diego, CA). 
 
Identification of Differentially Modified Gene Regions 
The 50-nt sequence reads were mapped to a reference genome (Mouse Genome 
Sequencing Consortium, 2007) using the Burrows-Wheeler Aligner software package (Li 
& Durbin, 2009). Illumina’s purity filter was used to eliminate duplicate reads and reads 
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that have 2 or more mismatches from further analysis. The 3’ ends of these aligned 
fragments are extended by 150-300bp in order to identify fragment density. The genome 
was divided into 32-nt ‘bins’ and the number of fragments (extended tags) that map to 
these bins were counted. Regions within the genome that showed a local enrichment of 
fragments (intervals or active regions) were found using SICER which has been shown to 
predict large protein binding domains (histone or polymerase binding regions) in histone 
modification ChIP data (Xu et al, 2014). An interval within 10,000 bp upstream or 
downstream of a gene region was counted as associated with that gene and identified by 
chromosome number, and a start and end coordinate. Variation of overlapping intervals 
between replicates were identified and defined by the most upstream start coordinate and 
the most downstream end coordinate. The active regions were annotated as upstream, in 
gene or downstream relative the Transcription Start Site (TSS) and the Transcription 
Termination Site (TTS) of the associated gene. The numbers of reads that correspond to 
each active region were counted in P0 and P8 samples. To identify regions of differential 
enrichment the active regions were analyzed using edgeR v2.14 software package 
(Robinson et al, 2010). Differentially modified regions were identified using FDR less 
than 0.01. Active regions corresponding to non-annotated regions in the reference 
genome were eliminated. This dataset was regrouped based on previously calculated FC 
values into two groups; active regions with FC values less than or equal to 0.67 that are 
therefore relatively enriched in the P0 sample, while active regions with FC greater than 
or equal to 1.5 that are therefore relatively enriched in the P8 sample. The P0-enriched 
(FC<1)  and P8-enriched (FC>1) active regions were filtered to select for active regions 
that correspond to the Proximal Promoter Region (PPR) upstream of the 5’-coding region 
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assigned as -1000 bp to +100 bp relative to the TSS. The resulting active regions located 
in the PPR were used to perform Gene Ontology and pathway analysis using DAVID 
(Dennis et al, 2003). The gene lists corresponding to the P0 and P8 active regions located 
in the PPR were classified into functional groups based on three ontologies as described 
by the Gene Ontology Database: molecular function, cell component and biological 
process. Pathway analysis was performed on the same gene lists using the Ingenuity 
Pathway Analysis software tool (IPA, Ingenuity Systems, http://www.ingenuity.com). 
 
Dosing of animals for PDE10A experiments 
All studies were performed on male rodents. Sprague Dawley (SD) rats (Charles River 
Laboratories, Margate, UK), C57BL/6 mice (Taconic Biosciences, Cambridge City, IN) 
and Bacterial artificial chromosome (BAC) transgenic Drd1a-tdTomato mice (The 
Jackson Laboratory, Bar Harbor, ME) were acclimatized for at least 3 days followed by 4 
days of saline injection to habituate them to the stress of handling and dosing. Animals 
were randomly assigned to treatment groups. They were treated either orally (PO) or 
intraperitoneally (IP) with saline, MP-10 (Selleckchem, Houston, TX), SKF82958 
(Sigma Aldrich, St. Louis, MO) or haloperidol (Tocris, Bristol, UK) at doses indicated in 
figure legends. Doses were selected on the basis of receptor occupancy data and 
published literature (Lewis et al, 1998; Mukherjee et al, 2001). Animals were euthanized 
at 3 hours post-dosing by cervical dislocation and brains were flash frozen over 
isopentane on dry ice followed by storage at -80°C prior to cryosectioning. The 3 hour 
time point was selected since MP-10 increases cAMP/cGMP levels for 1 to 4 hours after 
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an acute dose (Schmidt et al, 2008) and c-Fos immunoreactivity peaks between 1 and 3 
hours (Dragunow & Faull, 1989; Lensu et al, 2006). 
 
Cryosectioning/Immunohistochemistry of brains for c-Fos analysis 
Previously published protocols for c-Fos immunohistochemistry on flash frozen rodent 
brain were used (Sundquist & Nisenbaum, 2005). Brains were coronally sectioned at 7-
μm thickness on a Leica Cryostat CM3050 (Leica, Hiedelburg, Germany) at the 
following coordinates: Bregma 3.72 mm (rat prefrontal cortex), 1.68 mm (rat striatum), 
1.10 mm (mouse striatum), -3.60 mm (rat hippocampus and amygdala) and -4.56 mm (rat 
ventral hippocampus) according to the atlases of Watson and Paxinos (2004, Figure 5). 
Cryosections from each brain region were collected at 50 μm intervals on positively 
charged glass slides and incubated in 4% paraformaldehyde for 20 minutes at room 
temperature. Slides were then rinsed in TBST and stored at -80° C. 
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Figure 5: Diagrams from Paxinos and Watson Stereotaxic Atlas of the rat and mouse 
brain illustrating the brain regions assessed for c-Fos-immunoreactive cells. 
A) Diagrams of SD rat brain sections at the level of prefrontal cortex (Bregma 3.72 mm), 
striatum (Bregma 1.68 mm), amygdala and dorsal hippocampus (Bregma -3.60 mm) and 
ventral hippocampus (Bregma -4.56 mm) show regions of interest outlined. B-C) 
Diagrams of a mouse brain section at the level of striatum (Bregma 1.10 mm) shows the 
DLS and DMS and the five microscopic fields analyzed in BAC transgenic Drd1a-
tdTomato mice. PrL, Prelimbic Cortex; IL, Infralimbic Cortex; DLS, Dorsal Lateral 
Striatum; DMS, Dorsal Medial Striatum; AcbSh, Accumbens Shell. 
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For c-Fos immunohistochemistry, brain sections were rinsed in TBST buffer, incubated 
for 10 minutes in Dual Endogenous Enzyme Block (Dako, Carpinteria, CA), rinsed in 
TBST buffer and blocked with Protein Block (Dako) for 60 minutes using a Dako 
Autostainer Plus. Slides were incubated for 60 minutes with one of the two primary anti-
c-Fos antibodies; either a goat (Santa Cruz, Dallas, TX) or a rabbit antibody (Spring 
Bioscience, Pleasanton, CA) at 0.8 μg/mL concentration in the antibody diluent with 
background reducing agents (Dako). Issues with supplies of the antibody from Santa 
Cruz necessitated the use of the alternate antibody. Both c-Fos antibodies were tested 
under optimized conditions and shown to produce similar staining patterns with 
subregions of interest (Figure 6). 
 
 
Figure 6: Comparison of Spring Bioscience and Santa Cruz commercially 
available c-Fos antibodies. 
Quantitative analysis of c-Fos immunoreactive cell density in the DLS and DMS of SD 
rats, three hours after vehicle or MP-10 treatment at 30 mg/kg, PO. Each point represents 
a subregion of interest within an animal. Note the similar density of positive cells in all 
four groups of brain sections evaluated. 
41 
 
Slides were then rinsed 3X with TBST followed by addition of biotinylated secondary 
antibodies; a rabbit anti-goat or goat anti-rabbit IgG (Dako) for 30 minutes and then 
rinsed 3X with TBST buffer. Next, the slides were incubated with horseradish 
peroxidase-labelled streptavidin (Dako) for 10 minutes, rinsed 3X with TBST, incubated 
with 3,3’-Diaminobenzidine (DAB) for 5 minutes, and rinsed with TBST followed by 
distilled water. Sections were counterstained with hematoxylin for 30 seconds and 
coverslipped using Cytoseal XYL (Thermo Scientific, Kalamazoo, MI). 
 
For the immunofluorescence studies on BAC transgenic Drd1a-tdTomato mouse, after 
the incubation with the primary antibody, Alexa-fluor 488 labeled goat anti-rabbit IgG 
(Life Technologies, Grand Island, NY) was added to the slides for 60 minutes, then 
rinsed 3X with TBST washing buffer. Sections were counterstained with 10 μg/mL 
Hoechst 33342 (Life technologies, Grand Island, NY) for 2 minutes and coverslipped 
using Fluorescent Mounting Media (Dako). 
 
Image Analysis of c-Fos in brain sections 
Images of the c-Fos-stained SD rat and C57BL/6 mouse brain sections were acquired at 
the 20X magnification on an Aperio ScanScope XT (version10.00.00.1805; Aperio, 
Vista, CA) by an investigator blinded to treatment groups and annotated for storage in the 
web-based software, Spectrum database (version10.0.1346.1806). Each brain region was 
outlined bilaterally using a manual inclusion drawing tool in the Aperio image viewer 
software, ImageScope (version10.0.36.1805). Regions of interest were outlined for each 
animal. For the MP-10 dose-response study, in addition to the dorsal lateral striatum 
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(DLS) and dorsal medial striatum (DMS), c-Fos immunoreactivity was analyzed in the 
prelimbic and infralimbic cortex, nucleus accumbens shell, amygdala and dorsal and 
ventral hippocampus were analyzed. Cells within each outlined region were counted 
using an adapted version of Aperio Nuclear Count algorithm using a macro that was 
designed to count the immunopositive nuclei. The number of positive nuclei per brain 
region were totaled, normalized by area sampled (mm
2
) and averaged to derive a value 
for each region per animal. Group averages, standard deviations, standard errors of the 
mean and 95% confidence intervals were computed for statistical analyses. 
 
Images of the c-Fos-stained BAC transgenic Drd1a-tdTomato mouse brain sections were 
acquired on a Panoramic MIDI fluorescent digital slide scanner (3DHISTECH, Budapest, 
Hungary). Five 40X images were collected. In addition to the DLS and DMS, central 
striatal regions were included, so that region selection was not a bias. Images were 
annotated for storage on the instrument controller using a nomenclature system that 
blinded both, the treatment groups and regions of interest. Manual analysis of images was 
performed by counting cells with c-Fos signal (green, Alexa-Fluor 488) and nuclear 
counterstain (blue, Hoechst 33342) with and without dopamine D1 receptor signal (red, 
tdTomato). Thus four categories of cells were recorded: (i) c-Fos-expressing (c-Fos+) 
cells in D1+ neurons (+ red, + green, + blue), (ii) c-Fos+ cells in D1- neurons (- red, + 
green, + blue), (iii) D1+ neurons without c-Fos (+ red, - green, + blue) and (iv) neurons 
without D1 or c-Fos (- red, - green, + blue). The raw counts per image of all four 
categories were normalized to total number of cells. Both D1(-) cells (i.e., presumably 
D2(+) cells) and D1(+) cells were either categorized as c-Fos(+) or c-Fos(-). Averages for 
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each treatment group, standard deviations and standard errors of the mean were computed 
for statistical analyses. 
 
Image Analyses and Statistical Methods of PDE10A studies 
Study power was estimated based on effect size in pilot studies, which demonstrated that 
5 animals per treatment group would yield 80% power to observe 15% induction of c-
Fos. To ensure sufficient power, 6 animals were assigned to each treatment group. 
Statistical analyses of average c-Fos immunopositive nuclei density was performed by 
Analysis of Variance (ANOVA). Following significant effects, group-wise comparisons 
were performed using the Tukey-Kramer test. All tests were conducted at the two-sided 
0.05 alpha level and correspondingly all confidence intervals were constructed at 95%. 
The response variables were evaluated for normality using Kolmogorov-Smirnov’s test 
and evaluated for heterogeneity of variance using Levene’s. Results from animals with no 
measurable c-Fos induction were included in the statistical model and are represented 
with a value of zero. 
 
In order to illustrate the regional pattern of c-Fos density across treatment groups, a c-Fos 
dominance index was computed by subtracting the signal in the DMS from that in the 
DLS for each animal followed by computation of the group average and 95% confidence 
intervals. Positive values and confidence intervals greater than zero indicate that the 
signal in the DLS is statistically greater than that in the DMS. 
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CHAPTER 4: MICROGLIA AND ASTROCYTE PHENOTYPES ARE 
REGULATED BY FIBRILLAR ALPHA-SYNUCLEIN 
Introduction 
The precise nature of pathologic forms of α-synuclein is a matter of intense research. 
Prevailing data suggest that aggregated, but not monomeric α-synuclein, is the toxic 
species (Dehay et al, 2015). Although Lewy pathology is intracellular, neuronal and glial 
cells come in contact with α-synuclein aggregates released from dying neurons, by 
unconventional exocytosis or during the process of phagocytosis of damaged neurons by 
microglial cells (Lee et al, 2014). Additionally, emerging data indicate that α-synuclein 
monomers and aggregates may be released from neurons and transported between cells in 
a prion-like manner, further exposing surrounding neurons and glia to potential toxic 
effects of α-synuclein (Luna & Luk, 2015). 
 
Imaging, histological and biochemical studies have demonstrated that 
neuroinflammation, and specifically, microgliosis is a major pathophysiology of PD 
(Wang et al, 2015) and contributes to the progressive death of dopaminergic neurons 
(reviewed by Sanchez-Guajardo et al, 2013a). Microglia are the resident immune cells 
that constantly survey and dynamically respond to their microenvironment to take on a 
variety of homeostatic functions critical for maintaining the health of the neurons and 
astroglia (Masuda & Prinz, 2016). These sensing functions are mediated via the 
expression of a large repertoire of proteins such as cytokine receptors, chemokine 
receptors, scavenger receptors, pattern recognition receptors, purinergic receptors, ion 
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channels and neurotransmitter receptors (Kierdorf & Prinz, 2013). These receptors enable 
microglia to sense extrinsic changes such as pathogens, pH, adenosine triphosphate 
(ATP), amino acids, neurotransmitters and cytokines in the microenvironment 
(Kettenmann et al, 2013). When the receptor-ligand interaction occurs, it triggers a 
cascade of molecular events to alter the activation state and thereby functions of 
microglia (Shemer et al, 2015). Thus, microglia can exist in a continuum of molecular 
and morphological phenotypes, which at extremes are termed the classical activation state 
(M1-like) and alternative activation state (M2-like). In the classical profile, microglia 
express and release pro-inflammatory and cytotoxic molecules like tumor necrosis factor-
alpha (TNF-α), interleukin-6 (IL-6), interferon-gamma (IFNγ) and nitric oxide 
contributing to amplification of responses during injury or infection. In the alternative 
activation state, however, microglia are characterized by the release of anti-inflammatory 
molecules like IL-10 and arginase, which are involved in repair mechanisms. An 
imbalance in the activation state of microglia favouring the classical activation state is 
implicated in the neuroinflammatory pathophysiology of PD (Moehle & West, 2015). 
These data have led to a number of studies to investigate whether α-synuclein alters the 
activation state of microglia through studies on primary cultures as well as microglial cell 
line such as the BV-2 cells (Sanchez-Guajardo et al, 2013a). 
 
While microgliosis has been shown to be a major contributor to the pathology of PD, 
astroglia, the most abundant glial cell type, also has a role in PD pathology (Croisier & 
Graeber, 2006). In moderate to severe cases of disease, astrocytes enter a state of reactive 
gliosis and begin to secrete molecules such as TNFα and IL-1β, which are thought to 
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regulate and further modulate the classical activation state of microglia, maintaining 
neuroinflammation (Medeiros & LaFerla, 2013; Sanchez-Guajardo et al, 2013a). Several 
studies have begun examining extracellular α-synuclein-mediated effects of astrocytes 
(Lee et al, 2010b). These direct effects of α-synuclein have been shown to be mediated 
through TLR4 receptors, which can induce mitochondrial dysfunction, increase nuclear 
factor κB activity along with increases in expression of GFAP, pro-inflammatory 
cytokines, adhesion molecules and MMPs (Braidy et al, 2013; Fellner et al, 2013; Joo et 
al, 2010; Klegeris et al, 2006; Klegeris et al, 2007; Koob et al, 2010; Lee et al, 2010c; 
Rannikko et al, 2015; Tousi et al, 2012). In vivo, reactivity of astrocytes is correlated to 
the distance of the neighboring injury following direct injection of α-synuclein or 
endogenous α-synuclein inclusions (Ahn et al, 2012; Gan et al, 2012; Gu et al, 2010; 
Hishikawa et al, 2005; Nakamura et al, 2016; Radford et al, 2015; Sacino et al, 2013; 
Shrivastava et al, 2016; Tong et al, 2015; Valera et al, 2014; Wakabayashi et al, 2000). 
Based on the current literature, it is clear that astrocytes play a role in synucleinopathies, 
however further studies of astrocyte responses to different forms of α-synuclein should be 
completed. 
 
Unfortunately, the existing literature is confusing and full of contradictory results. Thus 
monomeric, small molecular weight oligomeric or larger fibrillar α-synuclein have all 
been shown to either induce or fail to induce the pro-inflammatory, classical activation of 
microglial and macrophage-like transformed cell lines as well as primary microglia and 
astrocytes (Sanchez-Guajardo et al, 2015). One reason for the lack of consistency may be 
that few studies have conducted robust concentration- and time-response studies and 
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side-by-side comparison of monomeric versus adequately characterized aggregated α-
synuclein in a given cell type and experimental conditions. Even those studies that have 
performed direct comparison of α-synuclein aggregates versus monomeric α-synuclein 
have reported inconsistent results, which may be due to experimental differences such as 
concentrations of α-synuclein tested (Beraud et al, 2013; Codolo et al, 2013; Daniele et 
al, 2015; Fellner et al, 2013; Joo et al, 2010; Klegeris et al, 2006; Koob et al, 2010; Lee et 
al, 2010a; Park et al, 2008; Rannikko et al, 2015; Russo et al, 2015). Similarly, different 
groups have reported inconsistent results on the effects of α-synuclein on phagocytic 
activity (Boza-Serrano et al, 2014; Fellner et al, 2013; Park et al, 2008). Thus, it remains 
unclear whether monomeric or aggregated α-synuclein induces proinflammatory 
phenotype in microglia-like cells and its functional effect on phagocytosis. 
 
Characterization of α-synuclein fibrils 
Sister aliquots of a single lot of recombinant α-synuclein monomeric and fibrillar 
preparations were used for all the studies detailed here. To characterize the fibrils prior to 
testing on cell cultures, we determined protein concentrations and assessed thioflavin-T 
binding, Western blotting and TEM. As expected, there was no binding of thioflavin-T to 
monomeric α-synuclein whereas fibrillar α-synuclein showed high level of binding 
(Figure 7A). SDS-PAGE followed by immunoblotting with an α-synuclein antibody 
showed low molecular weight bands for the monomer preparation at ~14 and 42 kDa, 
whereas the fibrillar preparation showed the expected smear of multimeric proteins 
ranging from 35 to 250 kDa (Figure 4.1B). Analysis of fibrils by TEM revealed straight, 
elongated and uniform filaments (Figure 4.1C). Taken together, the analyses of the 
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agitated recombinant α-synuclein indicate the presence of beta-sheet containing, SDS-
resistant fibrils. 
 
 
Figure 7: Characterization of α-synuclein fibrils 
A) Relative fluorescence units (RFU) of thioflavin-T added to serum-free media (SFM), 
monomeric α-synuclein (M) or fibrillar α-synuclein (F). Thioflavin-T binding signal of 
4957 Arbitrary Units (A.U.) in the fibrillar α-synuclein (F; agitated and dialyzed solution) 
confirms monomer to fibril conversion of α-synuclein compared to a signal of 311 A.U. 
at 494 nm of the monomeric (unagitated) α-synuclein (M), comparable to the background 
of thioflavin-T with serum-free media (SFM). B) Monomeric (M) and fibrillar (F) α-
synuclein were assessed by Western blot under reducing conditions. Note the absence of 
any multimeric forms evident as high molecular weight products in monomeric α-
synuclein. Fibrillar α-synuclein separates at high molecular weight, which indicates 
presence of multimeric fibrillar protein. C) Representative image of TEM analysis of 
fibrillar α-synuclein. Filaments from fibrillar α-synuclein have lengths of 0.25 to 2.0 μm 
and a mean width of 14.1 nm. Magnification bar = 0.2 μm. 
 
BV-2 microglial cells show dose-dependent induction in Il6 mRNA levels following 
treatment with fibrillar, but not monomeric α-synuclein 
IL-6 is a pro-inflammatory cytokine that marks the classical activation state of microglia. 
To understand the dose-response relationship for fibrillar α-synuclein-mediated activation 
of BV-2 cells, we examined Il6 mRNA levels at 3 hours following treatment with fibrillar 
α-synuclein at 0.03, 0.3 or 3 μg/mL or monomeric α-synuclein at 3 μg/mL. Monomeric α-
synuclein did not affect Il6 levels but a dose-dependent response was produced by 
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fibrillar α-synuclein, with the highest concentration showing a statistically significant 
effect (Figure 8A). Importantly, the increase in Il6 was seen in the absence of 
cytotoxicity, as assessed by LDH release in the media (Figure 8B). The BV-2 cell lysate 
was used as an analytical positive control and demonstrates the validity of our LDH 
measurements. 
 
 
Figure 8: Increasing dose of recombinant α-synuclein fibrils increased Il6 mRNA 
in vitro without altering microglia cell death after 3 hours. 
BV-2 microglia were treated with 3 μg/mL of monomeric α-synuclein or fibrillar α-
synuclein at different concentrations (0.03, 0.3 or 3 μg/mL) or serum-free media prior to 
measuring Il6 mRNA levels which significantly increased at the highest concentration of 
fibrillar α-synuclein treatment tested, when compared to serum-free media. * p<0.05. B) 
BV-2 microglia treated with 3 μg/mL of monomeric α-synuclein, fibrillar α-synuclein at 
different concentrations (0.03, 0.3 or 3 μg/mL) or serum-free media (SFM) did not 
increase release of lactate dehydrogenase (LDH) into the culture media as measured by 
optical density (OD) at 490 nm. Total cell lysate of SFM treated BV-2 cells served as a 
positive control for LDH release. * p<0.05, ANOVA followed by student’s t. 
 
BV-2 microglial cells are classically activated by fibrillar but not monomeric α-
synuclein: histological and morphological markers 
Having assessed an active dose of fibrillar α-synuclein, we went on to examine directly 
BV-2 activation by monitoring the expression of IBA1, a marker of classically activated 
microglia (Ito et al, 1998). Cultured mouse BV-2 microglial cells were incubated with 
serum-free media, monomeric α-synuclein (3 μg/mL), fibrillar α-synuclein (3 μg/mL), or 
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IFNγ (0.1μg/mL) as a positive control for 3 or 24 hours followed by fixation and 
immunohistochemistry for IBA1. Compared to the serum-free media control, the number 
of IBA1 expressing BV-2 cells increased time-dependently following treatment with 
fibrillar α-synuclein and IFNγ but not those treated with monomeric α-synuclein (Figure 
9A-D). Quantitative assessment of IBA1 immunofluorescence confirmed these findings 
(Figure 9E). 
 
 
Figure 9: α-Synuclein fibrils and IFNγ activate BV-2 microglia compared to monomeric 
α-synuclein 
A-D) BV-2 microglia treated with serum-free media (SFM, A) 3 μg/mL α-synuclein 
monomer (B), 0.1 μg/mL interferon γ (IFNγ) (C), or 3 μg/mL α-synuclein fibrils (D) 
prior to double-labelling with IBA1 and Hoechst stain. Images show IBA1 fluorescence 
(red) and Hoechst (blue). E) Mean fluorescent intensity of IBA1 in cells treated with 
serum-free media (SFM), 3 μg/mL monomeric α-synuclein (M), 3 μg/mL fibrillar α-
synuclein (F) or 0.1 μg/mL IFNγ for 3 or 24 hours (hr). * p<0.05, ANOVA followed by 
student’s t. 
 
Time course of α-synuclein fibril induces increased mRNA levels and release of 
classical activation markers in BV-2 cells 
Classical activation of microglia is accompanied by an increase in the expression of 
mRNA encoding pro-inflammatory cytokines, Il6, Tnf, and nitric oxide synthase 2 
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(Nos2). Hence, we assessed the time-course of changes in the mRNA levels of these 
markers after treating BV-2 cells for 3, 9, or 24 hours with serum-free media, LPS 
(positive control, 100 ng/mL), monomeric α-synuclein (3 μg/mL), and fibrillar α-
synuclein (3 μg/mL). As expected, bacterial LPS-treated cells dramatically increased Il6, 
Tnf and Nos2 mRNA levels. Treatment with monomeric α-synuclein failed to induce Il6, 
Tnf or Nos2 levels at any time point examined. In contrast, aggregated α-synuclein 
robustly increased the expression of all three mRNAs at all time points examined, but 
with a time course that was somewhat distinct for each mRNA (Figure 10A-C). Thus Il6 
was significantly and similarly elevated by fibrillar α-synuclein at 3 and 9 hours but 
began to recover at 24 hours; this pattern was similar to the response produced by LPS. 
Tnf peaked at 3 hours and began to recover at 9 hours following treatment with fibrillar 
α-synuclein as well as LPS. At 24 hours, the LPS-induced Tnf response showed complete 
recovery but remained significantly high in fibrillar α-synuclein treated cells. Finally, 
Nos2 induction appeared to have a biphasic time course in response to both fibrillar α-
synuclein and the LPS, with 9 hours showing the least induction followed by a second 
phase of induction apparent at 24 hours. In order to examine whether the increase in Il6 
and Tnf levels is associated with an increase in the release of these inflammatory 
cytokines, we assessed IL-6 and TNFα protein levels in the media under an extended 
time-course. A significant increase in secreted IL-6 and TNFα was noted after treatment 
with both LPS and fibrillar α-synuclein but not monomeric α-synuclein (Figure 10D and 
E). The peak increases in the protein levels in the media occurred at 9 hours, which were 
time-shifted compared to the peak increases in the mRNA levels of Il6 and Tnf. By 15 
hours, both cytokines appeared to be in the recovery phase but the levels remained 
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significantly high at 24 hours. It is important to note that none of the treatments affected 
LDH release (data not shown), indicating that the changes in the cytokine protein levels 
in the media result from the secretion of the cytokines and not cell death. 
 
 
Figure 10: mRNA markers of classical activation and cytokine release increase in the 
presence of fibrillar α-synuclein compared to monomeric α-synuclein 
Relative levels of Il6 (A), Tnf (B) and Nos2 (C) were determined by RT-qPCR at 3, 9, 
and 24 hours (hr) of treatment with serum-free media (SFM), 0.1 μg/mL LPS, 3 μg/mL α-
synuclein monomer or 3 μg/mL α-synuclein fibril. Levels of IL-6 (D) and TNFα were 
quantified from media by ELISA from BV-2 microglia treated for 3, 6, 9, 15, and 24 
hours (hr) with serum-free media (SFM), 0.1 μg/mL, 3 μg/mL α-synuclein monomer or 3 
μg/mL α-synuclein fibril. * p<0.05, ANOVA followed by student’s t. 
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α -Synuclein fibrils increase TNFα levels in primary microglia 
Since BV-2 cells are a transformed cell line, we wanted to confirm that primary microglia 
are also classically activated by α-synuclein fibrils in a manner similar to what we 
observed in the BV-2 cells. CD11b-expressing microglia cells were isolated and cultured 
from early postnatal age as well as 5 month old mice. Primary microglial cultures were 
treated for 24 hours under serum-free conditions with monomeric α-synuclein, fibrillar α-
synuclein or LPS as a positive control and the secretion of the pro-inflammatory 
cytokine, TNFα, in the media was examined. As seen with BV-2 cells, monomeric α-
synuclein failed to alter TNFα secretion whereas α-synuclein fibrils increased TNFα 
levels in the media by nearly 3-fold (Figure 11A and B). Taken together, these data 
indicate that BV-2 cells are a viable model to characterize the effects of α-synuclein on 
activation states of microglia. 
 
 
Figure 11: Primary microglia increased TNFα release in the presence of fibrillar 
α-synuclein 
Levels of TNFα released by primary microglia isolated from postnatal day 8 (A) or 5-
month old (B) WT mice were quantified from media by ELISA after treatment for 24 
hours with serum-free media (SFM), 3μg/mL α-synuclein monomer, 3 μg/mL α-
synuclein fibril or 0.1 μg/mL LPS. * p<0.05, ANOVA followed by student’s t. 
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α-Synuclein fibrils increase TNFα levels in primary astrocytes 
Although a significant increase in IL-6 and TNFα was seen in microglia, it is possible 
that other glial cells contribute to α-synuclein-mediated pro-inflammatory responses. To 
understand the α-synuclein responses of astrocytes, another glial cell type with the ability 
to secrete cytokines and regulate microglia, a pure population of GLAST-expressing 
mouse astrocytes was treated for 24 hours. These cells increased secretion of TNFα in 
both LPS and fibril treated cells when compared to monomeric α-synuclein. No increases 
of TNFα were present with control serum-free media or α-synuclein monomer treatment 
(Figure 12). 
 
 
Figure 12: Primary astrocytes increased TNFα release in the presence of fibrillar 
α-synuclein 
Levels of TNFα from primary astrocytes cultured from postnatal day 8 WT mice were 
quantified from media by ELISA after treatment for 24 hours with serum-free media 
(SFM), 3μg/mL α-synuclein monomer, 3 μg/mL α-synuclein fibril or 0.1 μg/mL LPS. * 
p<0.05, ANOVA followed by student’s t. 
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α-Synuclein fibrils decrease markers of alternative activation in BV-2 cells 
Unlike the pro-inflammatory state of classically activated microglia, the so-called 
alternative activation state is dominated by anti-inflammatory cytokine expression. In 
order to determine whether monomeric or fibrillar α-synuclein differentially affect the 
alternative activation state, we examined their effects of mRNAs for four prototypical 
alternative state markers, arginase 1 (Arg1), interleukin 10 (Il10), chitinase 3-like-3 
(Chi3l3) and mannose receptor C1 (Mrc1). Interestingly, α-synuclein fibrils, but not 
monomers, at 3 μg/mL reduced all four markers, albeit at different time courses. Thus a 
reduction in Arg1 was seen as early as 3 hours whereas that in Il10 and Chi3l3 was not 
seen until 24 hours and Mrc1 was reduced at 9 hours (Figure 13A-D). Another 
noteworthy observation is that LPS reduced only Mrc1 mRNA without affecting Arg1, 
Il10 or Chi3l3. Overall, these data indicate that α-synuclein fibrils shift the activation 
state of BV-2 cells away from the alternative, anti-inflammatory phenotype to a pro-
inflammatory phenotype. 
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Figure 13: mRNA markers of alternative activations decreased in the presence of 
fibrillar α-synuclein 
The relative levels of arginase 1 (Arg1, A), interleukin 10 (Il10, B), chitinase 3-like-3 
(Chi3L3, C) and mannose receptor C1 (Mrc1, D), and were determined by RT-qPCR in 
BV-2 cells at 3, 9, and 24 hours (hr) following treatment with serum-free media (SFM), 
0.1 μg/ml LPS, 3 μg/ml α-synuclein monomer or 3 μg/ml α-synuclein fibril. * p<0.05, 
ANOVA followed by student’s t. 
 
Effects of monomer and fibrils of α-synuclein on phagocytosis in BV-2 cells 
One major function of microglia is phagocytosis, which is affected by the activation state 
of these cells. Trem2 is a key receptor expressed exclusively on microglia and myeloid 
cells that promotes the phagocytic function of microglial cells while reducing pro-
inflammatory cytokine expression and inducing anti-inflammatory cytokine expression. 
Hence, we examined the effects of monomeric and fibrillar α-synuclein on the mRNA 
encoding Trem2 and its co-receptor, Tyrobp. Treatment of BV-2 cells with fibrillar α-
synuclein as well as LPS reduced Trem2 levels at 9 hours, with the reduction still 
significantly sustained at 24 hours (Figure 14A). Tyrobp levels were also reduced by 
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fibrillar α-synuclein at 24 hours but the LPS effect did not reach statistical significance 
(Figure 14B). Cd33 is another pattern-recognition receptor involved in phagocytosis but 
its mRNA levels were undetectable in BV-2 cells (data not shown).  
 
In light of the current data on Trem2 and Tyrobp as well as the conflicting literature about 
the effects of α-synuclein on phagocytosis, we conducted rigorous assessment of 
monomeric and fibrillar α-synuclein effects on this functional end-point in BV-2 cells. 
Three independent experiments demonstrated that both monomeric and fibrillar α-
synuclein treatment of BV-2 cells for 24 hours increases phagocytosis of E. coli 
bioparticles by ~25% when compared to serum-free media treatment (a representative 
example is shown in Figure 14C). On the other hand, LPS treatment did not affect 
phagocytosis despite reducing Trem2 levels. We used a 30-minute treatment with 
Cytochalasin D, an actin polymerization inhibitor, as an experimental positive control to 
demonstrate a decreased phagocytic ability of BV-2 microglia by over 50%. In the 
absence of bioparticles, very little background fluorescence was observed. 
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Figure 14: function increased and phagocytosis co-receptors Trem2 and Tyrobp 
decreased in BV-2 microglia following α-synuclein treatment 
Relative Trem2 (A) and Tyrobp (B) mRNA levels in BV-2 microglia following treatment 
with serum-free media (SFM), 0.1 μg/ml LPS, 3 μg/ml α-synuclein monomer or 3 μg/ml 
α-synuclein fibril for 3, 9 and 24 hours (hr). C) Percent phagocytosis effect was assessed 
following 24 hour stimulation with serum-free media (SFM), 0.1 μg/ml LPS, 3 μg/ml α-
synuclein monomer (M), 3 μg/ml α-synuclein fibrils (F), 10 μm Cytochalasin D for 30 
minutes or no particle negative control in BV-2 cells. * p<0.05, ANOVA followed by 
student’s t. 
 
Discussion 
The present study sought to systematically compare the effects of α-synuclein monomers 
and fibrils on the activation states of microglia as well as their phagocytic function. We 
prepared and characterized α-synuclein high molecular weight fibrils using a method 
similar to that reported by Beraud et al. (Beraud et al, 2013). The fibrillar nature of the 
aggregated α-synuclein was confirmed by TEM and thioflavin T binding. Furthermore, 
SDS-PAGE immunoblotting demonstrated the presence of SDS-resistant, high molecular 
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weight aggregates in the fibrillar preparation but not the monomeric preparation. In order 
to minimize the effects of lot-to-lot variability in α-synuclein aggregation, we prepared a 
large batch of aggregated α-synuclein and used sister aliquots for all the studies described 
here. 
 
Treatment of BV-2 cells, a murine microglial cell line, with different concentrations of 
fibrillar α-synuclein induced Il6 mRNA in a concentration-dependent manner, with 3 
μg/mL showing robust, reproducible and statistically significant effects in the absence of 
cytotoxicity. On the other hand, 3 μg/mL of monomeric α-synuclein did not affect Il6 
mRNA expression. This dose of fibrillar α-synuclein also induced hypertrophy of BV-2 
cells and expression of IBA1. Taken together, these data indicated that fibrillar α-
synuclein induces a pro-inflammatory, M1-like phenotype in BV-2 cells. To characterize 
and compare the activation state of BV-2 cells exposed to monomeric versus fibrillar α-
synuclein, we performed time-course experiments and analyzed alterations in mRNA and 
protein levels for markers of classical and alternative activation states. These data 
convincingly demonstrated increases in the mRNA encoding Il6, Tnf and Nos2 as well as 
release of IL-6 and TNFα in the media when BV-2 cells were treated with fibrillar α-
synuclein but not monomeric α-synuclein. Importantly, we also demonstrated that 
primary microglia cultures prepared from either neonatal or 5 month old mice show 
TNFα release in response to fibrillar α-synuclein but not monomeric α-synuclein and 
extended our experiments to show similar TNFα response from primary astrocytes. Thus, 
the classical activation and cytokine release is consistently induced by fibrillar α-
synuclein in a transformed cell line as well as primary microglia and astrocytes. 
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Interestingly, fibrillar α-synuclein reduced the expression of markers of alternative 
activation, Arg1, Il10, Chi3l3 and Mrc1, whereas monomeric α-synuclein did not induce 
changes in any M2 marker. In general, the effects of fibrillar α-synuclein on classical 
activation were similar to those of an endotoxin. On the other hand, LPS treatment had 
minimal effects on alternative activation markers, agreeing with previous reports of acute 
treatment of primary microglia with LPS (Tanaka et al, 2015). These data demonstrate 
that fibrillar α-synuclein shifts microglial cells to the classical activation state and 
decreases markers of alternative activation, whereas monomeric α-synuclein has no effect 
at concentrations tested. 
 
The differential effects of fibrillar versus monomeric α-synuclein on markers of classical 
activation observed in our studies are generally consistent with the report by Beraud et al. 
(Beraud et al, 2013). One notable difference was that the minimally effective 
concentration we observed for significant induction of the classical activation state in 
BV-2 cells was 3 μg/mL (~200 nM), which is 4-fold higher than that reported by Beraud 
et al. (Beraud et al, 2013). However, this small discrepancy could be explained by the 
differences in their method to prepare fibrillar α-synuclein. Following aggregation, 
Beraud et al. (Beraud et al, 2013) used size separation to enrich their preparation for 
aggregated species >150 kDa in size, which may have increased the potency of their 
preparation. In fact, a comparison of their data on TNFα release between Beraud et al., 
2013 and an earlier paper (Beraud et al, 2011) where they did not enrich for larger 
aggregates indicates that the enriched preparation does have a higher potency as 
evidenced by greater TNFα release. 
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It is important to discuss the relevancy of 3 μg/mL (~200 nM) concentration of α-
synuclein used in the present studies to PD pathophysiology. Previously, we have 
assessed α-synuclein release in cultures of a variety of cells, including iPS-derived 
neurons. These studies consistently show that ~10% of intracellular α-synuclein is 
released into the media (data not shown). Taken together with estimated concentrations 
of 2 to 5 μM of total α-synuclein in PD brains (Cremades et al, 2012; Iwai et al, 1995; 
Westphal & Chandra, 2013), we contend that the concentration of 200 nM used here is 
within range of expected interstitial fluid levels of α-synuclein. Of course, studies that 
directly measure interstitial α-synuclein levels in rodent and human brains are needed to 
definitively establish the pathogenic significance of the α-synuclein concentration tested 
here. 
 
Our results of selective effects of fibrillar α-synuclein on inducing a pro-inflammatory 
phenotype in microglial cells appear to be in contradiction with those of others (Beraud et 
al, 2013; Codolo et al, 2013; Lee et al, 2010a) and a more recent report (Hoenen et al, 
2016), which associates wild-type monomeric α-synuclein with weak pro-inflammatory 
induction. Collectively, these studies report that both monomeric and non-sonicated α-
synuclein pre-formed fibrils induced markers of classical activation such as reactive 
oxygen species, nitric oxide, nuclear translocation of nuclear factor κB, IP-10, TNFα and 
IL-1β in primary microglia/monocytes or mixed glial culture. However, these studies 
tested 1 to 10 μM of α-synuclein monomers and fibrils, a range significantly higher than 
200 nM of fibrillar α-synuclein tested in the present studies. Whether such high 
62 
 
concentrations of monomeric or aggregated α-synuclein have relevance to PD 
pathophysiology remains to be seen. 
 
Effects of α-synuclein in primary astrocytes were examined to understand the response of 
another glial cell type, which can regulate the state of microglia. Astrocytes are able to 
produce inflammatory cytokines and chemokines that communicate with neighboring 
microglia. Stimulation of astrocytes by α-synuclein was shown to activate pro-
inflammatory cytokine release, which may induce secondary effects such as classical 
microglia activation, to create a potentially amplified inflammatory response (Lee et al, 
2010b). The differential effects of fibrillar versus monomeric α-synuclein are consistent 
with classical activation of the pro-inflammatory state of microglial cells in present 
experiments. Few published reports have examined cytokine release following treatment 
with monomer and fibrillar α-synuclein in astrocytes. Dramatic changes in cytokine 
expression following neuron-secreted α-synuclein exposure over 24 hours were 
previously reported (Lee et al, 2010c). Also, IL-1-induced CXCL10 protein expression 
and secretion was potentiated by co-exposure with aggregated α-synuclein (Tousi et al, 
2012). However, these results along with the current findings conflict with other literature 
reports. Monomeric α-synuclein treatment has been shown to increase MMP9, a pro-
inflammatory mediator, compared to aggregated treatment (Joo et al, 2010). Also, TLR4, 
GFAP, IL-6, and ICAM1 have all shown to be increased in astrocytes when treated with 
the monomeric α-synuclein (Klegeris et al, 2006; Koob et al, 2010; Rannikko et al, 
2015). The main discrepancy of these experiments is that the tested concentrations are 
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again much higher than in present studies and presumed physiologically relevant 
concentrations. 
 
To investigate the functional implications of altered activation state, we studied 
phagocytic capacity of α-synuclein treated BV-2 cells 24 hours after treatment with 
monomeric or fibrillar α-synuclein. This time point was selected for functional 
assessment since we observed a sustained change in a number of M1-associated 
molecular and morphological markers. These studies showed that both monomeric and 
fibrillar α-synuclein similarly enhanced phagocytosis in BV-2 cells. These data are 
consistent with other reports (Boza-Serrano et al, 2014; Fellner et al, 2013). Fellner et al. 
included primary microglia and observed that 3 μM of soluble monomers as well as 
fibrillar α-synuclein increased phagocytosis. Note that they assessed phagocytosis at 2 
hours of treatment, a significantly earlier time point, which may have required a higher 
concentration to observe an effect of α-synuclein. Boza-Serrano et al. also demonstrated 
an increase in phagocytosis by BV-2 cells, but again at a higher concentration of 20 μM 
of fibrillar α-synuclein and following a shorter treatment duration of 12 hours (Boza-
Serrano et al, 2014). There is one literature report that shows results that contradict ours 
as well as the literature discussed above. Thus Park et al. reported an increase in 
phagocytosis by BV-2 cells following 24 hour treatment with 5 μM monomeric α-
synuclein but a decrease by 1 μM fibrillar α-synuclein (Park et al, 2008). The reasons 
underlying the apparent discrepancy remain unclear but indicate the importance of 
conducting systematic concentration- and time-response studies to select optimal 
experimental conditions. 
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In order to evaluate a possible mechanism associated with phagocytic effects of α-
synuclein discussed above, we focused on the TREM2 pathway. TREM2 and its adapter 
protein, TYROBP, are highly expressed in microglia (Colonna & Wang, 2016), where 
they are thought to regulate phagocytic function and inflammation (Painter et al, 2015; 
Thrash et al, 2009). Although not consistently replicated, TREM2, and specifically the 
R47H variant, has been implicated in the etiology of PD through genetic association 
(Mengel et al, 2016; Rayaprolu et al, 2013). We assessed the effects of α-synuclein on 
mRNA levels of Trem2 and Tyrobp. Contrary to our expectations founded on the 
observed increases in phagocytosis discussed above, fibrillar α-synuclein reduced the 
levels of Trem2 and Tyrobp whereas monomeric α-synuclein was without effect.  
 
Previous studies (Beraud et al, 2011; Fellner et al, 2013; Rannikko et al, 2015; Stefanova 
et al, 2011; Su et al, 2009; Su et al, 2008) have implicated several microglial receptors in 
the uptake of α-synuclein. Thus deletion of toll-like receptor 4 (Tlr4), a signaling pattern 
recognition receptor, or Cd36, a scavenger receptor important for endocytosis, dampens 
α-synuclein mediated effects. Beraud et al. were unable to show significant decreases in 
several Tlr genes or Cd36 following α-synuclein treatment in BV-2 cells (Beraud et al, 
2011). Together, these data should prompt further interrogation of phagocytic receptors, 
including TREM2, and their capacity for phagocytosis following cellular interaction with 
α-synuclein. In the current study using the same cell line, we were unable to detect 
significant mRNA levels of Cd33, an innate immunity integrin-associated transmembrane 
protein implicated in neurodegeneration by genome-wide association studies. Further 
studies using a cell line or primary microglia with different genetic makeup should be 
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completed to understand the impact of CD33 on α-synuclein mediated uptake. Regardless 
of the mechanism, the increase in phagocytosis by both monomeric and aggregated α-
synuclein indicates that microglia may be involved in clearance of extracellular α-
synuclein. However, an inflammatory milieu may be induced only by α-synuclein 
aggregates, which may contribute to the progressive loss of dopamine neurons (reviewed 
by Sanchez-Guajardo et al, 2013a).  
 
In summary, through systematic dose-response and time-course studies and a 
combination of molecular and morphological markers, we have convincingly 
demonstrated that fibrillar α-synuclein but not monomeric α-synuclein, induces pro-
inflammatory, classical activation of BV-2 cells while reducing the alternative activation 
state. The selective increase in pro-inflammatory cytokines by fibrillar α-synuclein was 
observed also in primary mouse microglia, further strengthening the translational 
implications of the data from BV-2 cell cultures. In contrast to the molecular phenotypes, 
the phagocytic function of BV-2 cells was increased similarly by monomeric and fibrillar 
α-synuclein. This dichotomy between molecular phenotypes and phagocytic function of 
microglia exemplify the complexity in the relationship between molecular activation state 
markers and functions of microglia. Overall, the direct comparative analysis of the effects 
of α-synuclein monomers and fibrils shown here addresses several inconsistencies in the 
literature and support previous studies indicating that α-synuclein aggregation, but not 
monomeric α-synuclein, triggers an inflammatory milieu that may contribute to the 
chronic pathophysiology of Parkinson’s disease and other synucleinopathies.  
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Conclusions 
Overall the data shown here lead us to conclude that, fibrillar α-synuclein, but not 
monomeric α-synuclein, shifts the activation state of microglia towards the classical 
proinflammatory state. This response could contribute to the chronic neuroinflammatory 
pathophysiology and progressive neurodegeneration seen in PD brains. On the other 
hand, the phagocytic function of microglia is induced similarly by monomeric and 
fibrillar α-synuclein (Figure 15). 
 
 
Figure 15: Diagram of working hypothesis of α-synuclein-mediated regulation of 
microglia 
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CHAPTER 5: COMPARITIVE ANALYSIS OF MURINE RADIAL 
GLIA AND ASTROCYTE TRANSCRIPTOMES 
Introduction 
One aspect of the previous chapter examines the response of primary astrocytes in the 
presence of fibrillar α-synuclein, a pro-inflammatory stimulus. Astrocytes were shown to 
produce TNFα, an inflammatory cytokine, following this treatment. The release of this 
cytokine has been shown to induce a cycle of reactivity in astrocytes and induce many 
different functions related to reactive astrogliosis (Montgomery & Bowers, 2012). In 
some cases of neurodegenerative diseases or CNS injuries when TNFα is present, 
astrocytes de-differentiate, begin to proliferate and continue to release cytokines, which 
maintains reactive astrogliosis while forming a glial scar and may contribute to disease 
progression (Carrero et al, 2012). Although it is clear that interaction with released TNFα 
is involved in the trigger of astrocyte de-differentiation into a progenitor cell prior to 
proliferation, the mechanisms involved in the process of proliferation are far from 
defined. To begin to understand this process, it is important to determine the significant 
factors that are expressed during astrogenesis. One model used to study proliferating 
astrocytes is developmentally recapitulated during early postnatal stages within the brain 
(Molofsky et al, 2012). It is unlikely that complete overlap of factors found in developing 
astrocytes is found during reactive astrogliosis; however studying proliferation of 
astrocytes during the healthy state may be informative toward understanding a possible 
comparative factor involved during reactive astrogliosis and proliferation.  
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Many open questions still remain regarding the differentiation of radial glial cells and 
astrocytes and the roles they play in the developing central nervous system (Molofsky & 
Deneen, 2015). A comparative analysis of developing murine astrocytes and the cells 
from which the earliest astrocytes arise, postnatal radial glial cells, would be of interest in 
order to determine pathways and factors necessary for astrocytes to begin differentiation. 
 
Many studies have made attempts to investigate either radial glia or astrocyte precursor 
cells; however, these studies have been complicated by various issues, including 
methodologies that could possibly introduce artificial qualities within the cells 
(Beckervordersandforth et al, 2010; Cahoy et al, 2008; Johnson et al, 2015; Pollen et al, 
2015; Sirko et al, 2015; Thomsen et al, 2016; Zamanian et al, 2012; Zhang et al, 2014b), 
the use of shallow sequencing methods (Pollen et al, 2014), amplification of cells in vitro 
prior to mRNA isolation and sequencing (Beckervordersandforth et al, 2010; Sirko et al, 
2015; Zamanian et al, 2012), the use of impure populations of cells (Ayoub et al, 2011) 
or the use of novel non-validated markers (Zhang et al, 2016b). More importantly, a 
systematic comparative analysis of developing murine astrocytes to the radial glia from 
which they arise has not been performed. 
 
During the span of proliferative postnatal gliogenic events, many permissive signaling 
pathways are expressed (Molofsky et al, 2013). Transcription factors that have been 
implicated in astrocyte differentiation, include Nuclear Factor I-A (NFIA, Deneen et al, 
2006), NFE2L1 and ID3 (Molofsky et al, 2013) and SOX9 (Stolt et al, 2003). Pathways 
with multiple upregulated transcription factors during gliogenesis include BMP signaling 
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factors like SMAD1/5/8 (Scholze et al, 2014), Notch signaling factors like RBP/J, ID and 
HES1 (Nagao et al, 2007; Taylor et al, 2007; Zhou et al, 2010b), JAK/STAT related 
factors including CyclinD1, CBF-1 and STAT3 (Ge et al, 2002; Ma et al, 2015) and 
MEK signaling factors like ERM and ERK1/2 (Li et al, 2012). On the other hand, LHX2 
and nuclear receptor co-repressor (N-CoR) have been implicated as suppressors of 
astrocyte differentiation (Hermanson et al, 2002; Subramanian et al, 2011). Epigenetic 
regulation and DNA methylation also has a negative effect on astrocyte differentiation 
regulated by DNA methyltransferase I (Fan et al, 2005). 
 
In the current study, systematic comparisons of the transcriptome of a large population of 
whole brain radial glial cells and astrocyte precursors have been analyzed based on gene 
expression. This study focuses on the characterization of acutely isolated and purified 
GLAST (+) cells at P0 and P8. GLAST positivity and co-expression of cell type-specific 
markers confirm the population and expression patterns of the cells of interest. 
Differential expression and pathway analyses identified novel factors as well as known 
genes that play a role in radial glia and astrocyte cell functions. Also, transcription factor 
analysis revealed clusters of differentially expressed and regulated genes within these 
cells. Overall, this dataset will help to better understand the mechanisms of factors 
involved in radial glia and astrocyte precursors, using technical conditions with little 
known bias from the in vivo state of these cells. 
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GLAST-expressing astrocytes are generated postnatally in murine brain 
In order to perform a comparative analysis of transcriptomes from radial glia and 
astrocyte precursor cells, a classification of the stages at which these cells exist in the 
mouse brain was needed. Moreover, it was imperative to characterize the expression of a 
protein that spans the cell membrane to be utilized for the isolation of these brain cells. 
To identify stages and confirm that GLAST, a transporter glycoprotein, was expressed in 
radial glial cells and astrocyte precursors, sections through developing and postnatal 
murine brains were co-labeled using immunofluorescence. Markers of radial glial cells 
and proliferating subventricular zone (SVZ) cells (VIMENTIN), neurons (microtubule 
associated protein-2; MAP2), oligodendrocytes (myelin basic protein; MBP), and 
astrocytes (nuclear factor 1A; NF1A) were compared at 4 stages in the cortex; 1) E16.5, a 
stage at which the large majority of cells will become neurons and low levels of 
astrocytes/oligodendrocytes are being produced, 2) P0, a low level of neurons and 
oligodendrocytes are generated, radial glial cells are decreasing, and proliferating 
astrocyte precursors are generated (Ge et al, 2012), 3) P8, mid-astrogenesis, and 4) P14, 
astrogenesis is nearly complete (Skoff & Knapp, 1991). Co-expression analyses of 
GLAST in mid-sagittal cortical sections revealed substantial co-localization of 
VIMENTIN at E16.5 (Figure 16A) and P0 (Figure 16E), and co-localization of NF1A at 
P8 (Figure 16J) and P14 (Figure 16N). Other markers did not show high levels of co-
localization. The degree of overlap per region in different stages was quantified and 
correlation coefficients (r) were calculated using confocal images. These calculations 
confirm co-localization of GLAST/VIMENTIN in E16.5 and P0 as well as 
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GLAST/NF1A in P8 and P14 cortex, while other stages and markers show low levels of 
co-localization (Figure 16Q). 
 
 
Figure 16: Immunohistochemical analysis of GLAST and cell specific markers in 
developing murine cortex 
Confocal images of sections double-labeled with GLAST (green) and cell type specific 
markers (red) at E16.5 (A-D), P0 (E-H), P8 (I-L) and P14 (M-P) in the frontal cortex of 
the developing murine brain during astrogenesis. A, E, I and M) Double-label for GLAST 
and VIMENTIN (radial glial marker). At E16 and P0 radial glial cells were present and 
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spanning the width of the cortex. Radial glial cells were replaced by a progenitor 
population in the subventricular zone at P8 and P14 (I, M). B, F, J and N) GLAST and 
NF1A (early astrocyte marker) double-label showed little colocalization at E16.5 and P0 
and increased colocalization at P8 and P14. C, D, G, H, K, L O, and P) Low levels of 
GLAST and MBP (oligodendrocyte marker) or GLAST and MAP2 (neuronal marker) 
were detected. Q) Quantitative colocalization (number of pixels) of each stage and cell 
type specific labeling with GLAST confirmed the high levels of colocalization of 
VIMENTIN at E16.5 and P0 and that of NF1A at P8 and P14. CP – Cortical Plate, SP – 
Subplate, IZ – Intermediate Zone, SVZ – Subventricular Zone, VZ – Ventricular Zone, 
VIM- VIMENTIN, NF1A- Nuclear Factor 1A, MBP-myelin basic protein, MAP2- 
microtubule associated protein 2. Magnification bar in A = 50 μm. 
 
GLAST expression during astrogenesis was subsequently labeled in the developing 
cerebellum and olfactory bulb at the same stages (Figures 17 and 18). Co-localization of 
GLAST with radial glial and astrocyte precursors confirms peak production of GLAST 
expressing astrocytes at P8 (Figure 17). The peak co-localization of GLAST and NF1A 
was detected at P14 within the olfactory bulb (Figure 18). Since the bulk area analyzed 
displayed the most VIMENTIN/GLAST co-label at P0 and the most GLAST/NF1A co-
label at P8, P0 and P8 stages were chosen for further analysis. 
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Figure 17: Cerebellum IHC of GLAST and cell specific markers in developing mouse 
cerebellum. 
Confocal images of double-label immunofluorescence with GLAST (green) and cell type 
specific markers (red) at E16.5 (A-D), P0 (E-H), P8 (I-L) and P14 (M-P) in the 
cerebellum of the developing murine brain during astrogenesis. A, E, I and M) Double-
labeling of GLAST and VIMENTIN (radial glial marker) indicated colocalization at 
E16.5 and P0 and less colocalization at P8 and P14. B, F, J and N) GLAST and NF1A 
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(early astrocyte marker) labeling showed weak colocalization at E16.5 and increased 
colocalization at P8 and P14. C, G, K and O) MBP (oligodendrocyte marker) and; D, H, 
L and P) MAP2 (neuronal marker) labeling both indicate very low level colocalization 
with GLAST. Q) Quantitative colocalization (number of pixels) of each stage and cell 
type specific labeling with GLAST confirmed the high levels of colocalization of 
VIMENTIN at 16.5 and P0 and that of NF1A at P8 and P15. ML – Molecular Layer, PCL 
– Purkinje Cell Layer, GCL – Granular Cell Layer, NF1A- Nuclear Factor 1A, MBP-
myelin basic protein, MAP2- microtubule associated protein 2 Magnification bar in A= 
50 μm. 
 
 
Figure 18: Olfactory IHC of GLAST and cell specific markers in developing mouse 
olfactory bulb. 
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Figure 18 continued 
 
Confocal images of double-label immunofluorescence with GLAST (green) and cell type 
specific markers (red) at E16.5 (A-D), P0 (E-H), P8 (I-L) and P14 (M-P) in the olfactory 
bulb of the developing murine brain during astrogenesis. A, E, I and M) Double-labeling 
of GLAST with VIMENTIN (radial glial marker) indicated colocalization early at E16.5; 
however, low levels of colocalization are seen at P0, P8 and P14. B, F, J and N) GLAST 
and NF1A (early astrocyte marker) labeling showed little colocalization at E16.5, P0, P8 
and increased colocalization was detected at P14. C, G, K and O) MBP (oligodendrocyte 
marker) colocalized with GLAST at E16.5; however, colocalization was detected 
thereafter. D, H, L and P) Low levels colocalization of GLAST with MAP2 (neuronal 
marker) was seen. Q) Quantitative colocalization (number of pixels) of each stage and 
cell type specific labeling with GLAST confirmed the high levels of colocalization of 
VIMENTIN at E16.5 and P0 and that of NF1A at P8 and P14. GL – Glomerular Layer, 
EPL- External Plexiform Layer, MCL – Mitral Cell Layer, GCL – Granule Cell Layer, 
NF1A- Nuclear Factor 1A, MBP-myelin basic protein, MAP2- microtubule associated 
protein 2.  Magnification bar in A = 50 μm 
 
GLAST(+) radial glia and astrocytes isolated from P0 and P8 brains 
To determine if radial glia and astrocyte populations could be isolated from 
enzymatically dissociated P0 and P8 brains, a GLAST antibody (ASCA-1 clone; 
extracellular epitope) coupled to magnetic beads was used to isolate cells from whole 
mouse brain (depicted in Figure 19A). Using flow cytometry, the positively isolated 
fraction showed a 94% purity of GLAST (+) cells (Figure 19B), whereas 18% of the cells 
in the negative fraction were GLAST (+). Purified GLAST (+) cells at P0 and P8 (n=4 for 
each stage) were further analyzed by RNA sequencing to determine the radial glial and 
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astrocyte transcriptome immediately following isolation procedures as shown in a flow 
diagram (Figure 19C). Prior to RNA sequencing and differential gene analysis, high 
quality of RNA material (Figure 20) and library constructs (Figure 21) were confirmed. 
 
 
Figure 19: Isolation methods and diagrammatic representation of data analysis. 
A) A diagram of isolation procedures using neonatal (P0) or postnatal (P8) brains from 
C57BL/6J mice. A diagrammatic representation of brain dissociation into single cell 
suspension using anti-GLAST microBeads following magnetic separation and elution of 
radial glia from P0 brain or astrocyte precursors from P8 brain. B) Flow cytometry 
histograms representing an analysis of positively separated GLAST+ cells showing 94% 
positivity (red line) compared to the IgG control stained cells (black line) and negative 
elution showing 18% positivity (red line) compared to the IgG control stained cells (black 
line). C) Flow chart indicating the steps of RNA processing and analysis beginning with 
isolated cells and ending with the statistical analysis of transcripts identified by RNA-seq. 
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Figure 20: Quality assessment of RNA purity. 
Quality assessment from isolated RNA from 4 separate preparations of GLAST positive 
cells from each stage (P0 and P8) measured on an Agilent Bioanalyzer 2100. RNA 
integrity numbers (RIN) calculated by measuring 18S and 26S rRNA for each sample 
shown on a gel image along a Ladder of 25, 200, 500, 1000, 2000 and 4000 nucleotides 
(nt). Bioanalyzer output measured by fluorescent units (FU) is plotted showing peaks of 
18S and 26S, which are used to determine RIN values. All 8 samples were detected at or 
above 7.9 and represented above each individual sample plot. 
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Figure 21: Quality assessment of DNA library. 
Quality is based on integrity, size distribution and concentrations of the final library 
construct for each sample by Agilent Bioanalyzer 2100 and shown on a gel image for all 
8 samples along a Ladder of base pairs (bp). DNA quality output measured by FU is 
plotted for each sample library based on the intensity of gel images. 
 
Read mapping and cell type marker assessment of RNA sequence 
In order to compare the transcriptomes of P0 radial glia and P8 astrocyte precursor cells, 
RNA isolated from GLAST (+) cells was processed as explained above in Figure 19C 
and used in high throughput RNA profiling analysis. After sequencing, approximately 25 
million clean paired-end reads per sample were generated and subsequently mapped with 
the annotated mouse genome, mm9, and filtered to remove low quality reads (Figure 
22A). Total filtered reads were also separated by chromosomal region, revealing the high 
junctional alignment along with coding and untranslated 3’ regions (Figure 22B). 
 
79 
 
 
Figure 22: Number of sequencing reads mapped by region. 
A) Number of sequencing reads plotted on a log scale for all 8 samples. Sequencing reads 
were plotted for each sample including raw counts and after mapping to the mm9 genome 
and finally after filtering the reads for final alignment. B) Number of aligned sequencing 
reads were plotted on a log scale for each sample based on genomic region. Genomic 
regions plotted include coding, intergenic, intron, junction, mitochondrial, other-exon, 
promoter, untranslated 3’ (utr-3) and untranslated 5’ (utr-5). 
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Table 3: Mapped reads aligned by chromosome with reported counts and percentages within each sample. 
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Separation of aligned reads per chromosome indicates similar distributions of reads 
across samples based on the percentage of reads per chromosomes (Table 3). 
 
Additional confirmation of the cell isolation and RNA sequencing was completed by the 
selection of 45 known cell type-specific markers of various cells within the brain, 
including markers for radial glial cells, astrocytes, oligodendrocytes, neurons, and 
microglial cells. Calculation of FPKM for these markers in P0 and P8 samples 
demonstrates that mRNA isolated from P0 GLAST (+) cells was consistent with markers 
associated with radial glial cells, while mRNA isolated from P8 GLAST (+) cells was 
consistent with markers associated with astrocytes (Figure 23). Transcriptomes from P0 
and P8 GLAST (+) cells displayed low levels of known markers associated with 
oligodendrocytes, neurons and microglia. 
 
 
Figure 23: GLAST+ cell transcripts from P0 and P8 mouse brain were consistent with 
radial glial and astrocyte expression. 
Average FPKM and standard deviation were plotted on a split y-axis at 1000 for 45 
different cell markers in P0 and P8 cells. These markers are divided into cell specific 
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markers, with 2 radial glial-specific markers, 10 astrocyte and radial glial markers, 7 
astrocyte-specific markers, 9 oligodendrocyte markers, 9 neuronal markers and 8 
microglial markers. 
 
Differential gene expression and gene ontology 
To extend the investigation of common and unique characteristics between P0 radial glia 
and P8 astrocyte precursors, further RNA sequencing differential analyses were 
performed to compare their transcriptomic profiles. Differential expression analysis at the 
gene level following FPKM calculation was carried out using the EdgeR software 
package and reported by graphing p-value and fold change on a volcano plot (Figure 
24A). With a false discovery rate of less the 0.05 and an average FPKM greater than 1.0, 
a total of 6,278 transcripts were found to be differentially expressed. Of those genes that 
were differentially expressed, 3,334 were upregulated in astrocyte precursors compared 
to 2,944 in radial glial cells. 
 
 
Figure 24: Differential gene expression and gene ontology analyses. 
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Figure 24 continued 
 
A) Sequenced genes are plotted by negative log of the p-value and natural log of the fold 
change. Fold change of the genes are calculated using a ratio of the P8 value versus the 
P0 value. Genes with p-values less than 0.05 are significant and points are colored red. 
Genes with p-values greater than 0.05 are black. B) The list of significantly expressed 
genes were analyzed using the Panther gene ontology classification system. A summary 
of the classification for each of the genes enriched in P0 or P8 are shown by pie charts. 
 
The top 20 differentially expressed genes from radial glial cells and astrocyte precursors 
are listed in Table 4 and 5 respectively. Transcripts include those that are known to be 
expressed in radial glia, such as E-cadherin and carbonic anhydrase, in addition to other 
genes novel to radial glia, and/or genes with unknown functions (Table 4; Cammer & 
Zhang, 1992; Xu et al, 2011). The top 20 differentially expressed genes from astrocyte 
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precursors include transporters, channels, junctional proteins and intermediate filaments 
known to be expressed in astrocyte precursors, however, other membrane proteins and 
receptors with novel functions are also highly expressed (Table 5). A full list of genes can 
be found under the GEO accession number GSE83498.  
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Table 4: Top 20 differentially expressed transcripts from GLAST(+) radial glial cells. 
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Table 5: Top 20 differentially expressed transcripts from GLAST(+) astrocyte precursors. 
 
 
To determine if any of the differential transcript levels in radial glia or astrocyte 
precursors could be grouped into particular molecular pathways, the data was analyzed 
using the, Ingenuity Pathway Analysis tool (IPA; Ingenuity Systems, 
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http://www.ingenuity.com; Tables 6 and 7). A cut-off of 2-fold or greater change in 
mRNA level was applied, leaving 1,438 radial glial genes and 1,100 astrocyte precursor 
genes that were included in the analysis. IPA analysis revealed the presence of well-
known growth factor, axonal guidance, pluripotency, stem cell and glioblastoma 
signaling pathways in proliferating astrocytes along with neurotransmitter/hormone 
metabolism in the P0 radial glial cells (Table 6). Other notable pathways that are 
important in radial glial cells include inflammatory-related pathways, like endocytosis 
signaling, eicosanoid signaling, and inhibition of matrix metalloproteases, IL-1 signaling 
and LXR/RXR activation. Pathway analysis of astrocyte precursor genes reveals 
regulation of neurotransmitter and G-protein coupled receptor signaling, long term 
synaptic plasticity, cholesterol and fatty acid biosynthesis along with vascular 
homeostasis (Table 7). In addition, astrocyte precursor pathways also include 
neuroinflammatory-related pathways such as neuropathic pain signaling, CREB signaling 
and Amyotrophic Lateral Sclerosis signaling. 
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8
 
Table 6: Ingenuity pathway analysis of genes from radial glial cells 
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Table 7: Ingenuity pathway analysis of genes from astrocyte precursors 
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Functional classification of differentially expressed genes into ontologies was completed 
using the Panther classification system (pantherdb.org; Figure 24B). This analysis 
indicated that the two categories showing the largest changes between radial glial and 
astrocyte precursor cells were nucleic acid binding (13.2% increase from P0 to P8), and 
transcription factors (5.8% decrease from P0 to P8). Other gene ontology categories that 
showed a 1.0% or more change include; extracellular matrix proteins that were increased 
in P0 radial glia in comparison to P8 astrocyte precursors and oxidoreductases and ligases 
that were increased at P8 in comparison to P0. 
 
Transcription Factor Analysis 
Since the transcription factor ontology had the greatest dynamic changes between P0 and 
P8 in addition to the greatest abundance of differentially expressed genes (Figure 24), a 
more comprehensive analysis on those categories was completed. Transcription factors 
were placed into 7 classes; 1) High mobility group (HMG) box, 2) bHLH, 3) basic 
leucine zipper (bzip), 4) helix-turn-helix, 5) nuclear hormone receptor, 6) zinc finger, and 
7) transcription cofactors. Of the 124 transcription factors classified from the radial glia 
transcriptome, a large majority of the transcripts fell into 2 categories; zinc finger 
transcription factors and transcription cofactors, including Evi1, Teashirt homologue 2 
(Tshz2), Jade1, and lysine-specific demethylases 5A and 5B (Kdm5a; Kdm5b) (See Table 
8 for a full list of differentially expressed transcription factors in radial glia). The co-
activators found in radial glia included nuclear receptor co-activator 2 (Ncoa2), CREB 
binding protein (Crebbp), histone acetyl transferase p300 (p300), YES associated protein 
1 (Yap1), and Wilms’ tumour protein 1 interacting protein (Wtip). In contrast to radial 
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glial cells, message isolated from astrocyte precursors showed a distinct decrease in zinc 
finger transcription factors and co-factors, however increased expression of mRNA 
encoding HMG box, bHLH, and helix-turn-helix transcription factors (Table 9). 
Consistent with past studies, many of the HMG box messages that were found in 
astrocyte precursors were part of the Sry-related HMG box factors (Sox), including Sox1, 
2, 3, 4, 5, 6, 8, 11, and 21 (Gomez-Lopez et al, 2011; Nakajima-Koyama et al, 2015; 
Obayashi et al, 2009; Reiprich & Wegner, 2015; Schlierf et al, 2007). Messages encoding 
bHLH transcription factors included achaete-scute homolog 1 (Ascl1), transcription factor 
E2-alpha (Tcf3), oligodendrocyte transcription factor 1 and 2 (Olig1 and 2), while helix-
turn helix mRNAs included empty spiracles homeobox 2 (Emx2), paired homeobox 6 
(Pax6), prospero homeobox 1 (Prox1), and Iroquois homeobox 2 (Irx2). 
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Table 8: Differentially expressed transcripts identified as transcriptional regulators in 
radial glia 
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Table 8 continued 
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Table 8 continued 
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Table 9: Differentially expressed transcripts identified as transcriptional regulators in 
astrocyte precursors 
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Table 9 continued 
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Table 9 continued 
 
 
To validate expression patterns of transcription factors in the RNA-seq, RT-qPCR was 
used to validate the differential expression of 18 highly expressed transcriptional 
regulators (Figure 25B). Both techniques agreed with the directionality and differential 
expression of all 18 genes. When comparing mRNA levels between the two techniques, 
RNA sequencing detects a greater level for most of these factors. This finding was 
expected since the RNA sequencing methods used here were completed with paired-end 
sequencing to increase sensitivity and specificity of deep-sequencing techniques (Fang & 
Cui, 2011).  
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Figure 25: Analysis of transcription factors within GLAST+ radial glia and astrocyte 
precursors. 
A) 502 and 495 significant genes were identified using gene ontology as transcription 
regulators in P0 and P8 gene sets, respectively. Using the venn diagram software creator 
Venny, a comparative analysis of transcriptional regulators in P0 and P8 data sets shows 
451 regulators that were found in both data sets, 51 transcriptional regulators that are 
represented in the P0 dataset only (left-hand list), and 44 (right-hand list) regulators that 
are represented in the P8 dataset only. B) RT-qPCR validation of selected transcription 
factor genes using independent biological samples. The natural log fold change of mRNA 
levels of P8 over P0 samples using RNAseq and qPCR analysis. Both analyses were 
completed and plotted for 18 selected genes. 7 selected genes show a positive fold change 
for P8 cell mRNA levels when compared to P0 for both analyses. 11 selected genes show 
a negative fold change for P8 cell mRNA levels when compared to P0 for both analyses. 
 
To identify signals that may regulate a cohort of the transcription factors, a MetaCore 
transcription factor analysis was completed using the radial glial and astrocyte precursor 
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datasets. This functionality builds networks of enriched transcription factors and the 
genes they have been shown to regulate. The top 500 differentially enriched mRNAs 
from radial glia or astrocyte precursors were included in the analysis and the top 25 
significant transcription factors are reported for each cell type (Tables 10 and 11). Of 
these 25 factors, 10 were identified as unique to radial glia, and 9 were unique to 
astrocyte precursors (unique factors are highlighted in yellow). These unique 
transcription factors identified in Table 10 and 11 can be classified as regulators of one or 
more of the following ontologies; 1) cell proliferation, 2) inflammation (pro- and anti-
inflammation), 3) lipid biosynthesis or metabolism. 
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Table 10: Potential regulatory factors in radial glial cells. 
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Table 11: Potential regulatory factors in astrocyte precursors. 
 
 
Although some unique signals were found in the MetaCore analysis, there were also 
commonalities (outlined in grey, Tables 10. and 11). Since the analyses of the datasets 
highlighted differential mRNA levels, it was somewhat surprising to see so many factors 
common to both radial glial cells and astrocyte precursors. To understand the potential 
genes these factors were regulating in the two cell types, a network analysis of two 
common transcription factors, EGR1 and RELA, was completed (Figure 26). Figure 26 
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clearly shows that although EGR1 and RELA may play a role in both cell types, they 
regulate two completely different cohorts of genes in radial glia and astrocyte precursors. 
 
 
Figure 26: Metacore transcription factor regulation analysis for GLAST+ radial glia and 
astrocyte precursor datasets. 
EGR1 and RELA (p65 of NF-kB subunit) networks for both P0 and P8 GLAST+ cells 
including selected genes from pathway interaction analysis. Up-regulated genes in both 
P0 or P8 datasets are marked with red circles. Note the differences in networked 
interactions in both transcription factors between the two cell populations. 
 
Interactions with different combinations of protein partners may be one way that the 
same transcription factor can regulate the expression of different genes in different cell 
types. To test this, MetaCore was used to build a network map of factors present in the 
radial glial and astrocyte precursor datasets that regulate transcription and interact with 
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RELA. Figure 27 confirmed the presence of distinct binding partners that could interact 
with RELA in radial glia and astrocyte precursors. 
 
 
Figure 27: Metacore direct network interactions for RELA in radial glia and 
astrocyte precursors. 
Different potential binding partners for RELA are shown by connecting arrows with 
representative network objects found in radial glial cells (top) and astrocyte precursors 
(bottom).  
 
Discussion 
The present study compares the transcriptome of GLAST (+) brain cells isolated from 
radial glial cells at P0 and astrocyte precursors at P8. The appropriate stages to isolate 
each cell type was determined using double-label immunofluorescence using GLAST and 
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radial glial or astrocyte precursor markers in the cerebral cortex, olfactory bulb and 
cerebellum. Confirmation that radial glial cells and astrocytes were indeed isolated at P0 
and P8 respectively was determined by comparing FPKM in each dataset for different 
gene markers of radial glia, astrocyte, neurons, oligodendrocytes and microglia. We 
chose to use an antibody approach to purify astrocytes from whole brain cells expressing 
the extracellular epitope for the transmembrane glycoprotein, GLAST. GLAST is an 
abundant glutamate transporter and is predominantly expressed by astrocytes in the 
developing and neonatal mammalian CNS (Jungblut et al, 2012). Also radial glia, a cell 
within the astrocyte lineage, play important roles in development and are known to 
express GLAST (Shibata et al, 1997). During postnatal astrogenesis, secondary radial glia 
only persist in a few regions, such as Bergmann glia in the cerebellum, Müller glia in the 
retina, and radial glia in the dentate gyrus of the adult hippocampus, while mature 
astrocytes and precursors are present during P8 (Brunne et al, 2013). The cell populations 
and resulting datasets are well-founded and interpretation made about factors involved in 
astrocyte development using these data for comparison of astrogenesis is valid, however 
cell selection using this method may have an unknown bias toward individual cells with 
increased GLAST expression or increased sensitivity/responsiveness to glutamate or 
aspartate. Furthermore, high-throughput RNA sequencing methods were carefully 
conducted. Differential and pathway analyses were performed using EdgeR and IPA, 
exposing known genes and pathways within our cell populations of interest, along with 
novel genes with unknown relevance within astrocyte development. Interestingly, an 
unproportioned number of genes are known to be involved in transcriptional regulation. 
As mentioned above, proliferative gliogenesis involves many permissive signaling 
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pathways. Transcription factors, along with epigenetic regulation, are essential to the 
gene expression changes seen during these signaling events. Using bioinformatic 
techniques, our data has indicated combinatorial transcriptional cofactors could be 
involved in astrocyte proliferation and differentiation. 
 
Current data show differential expression within gene categories important for 
coordinating the intercellular movement of ions or water between astrocytes, which is an 
important function of astrocytes as they develop and form radiating processes (Simard & 
Nedergaard, 2004). Astrocytes have important functions for transporting glutamate, 
dopamine, glucose and many other important molecules in the CNS (Sery et al, 2015). 
The specific genes of the transporters group have functional relevance to these properties 
such as Slc4a5, Kcne2 and Clic6S13a4 transporters and Aqp1 water channel within the 
P0 cells. In P8 cells, neurotransmitter transporters include Slc1a2, Slc6a11 and Slc25a18 
along with Aqp4 water channel. Genes included in the canonical pathways within IPA 
analyses indicate that extracellular molecules, like growth factors such as BMPs and 
Wnts and collagens are important in the P0 cells. Specifically, BMP signaling is 
important for differentiation signals within proliferating astrocytes (Scholze et al, 2014; 
Sehgal et al, 2009).Genes included in canonical pathways for P8 cells include many 
neurotransmitter receptors, transporters and other channels which are important for 
astrocyte function. As an example, mRNA encoding GABA and glutamate receptors are 
represented in the IPA analysis, which is expected since these proteins have important 
roles in the astrocytes (Jo et al, 2014). 
 
106 
 
Analyses of possible upstream transcriptional regulatory factors in radial glia or astrocyte 
precursors belong in three functional categories. In the radial glial cells, factors necessary 
for pluripotency were found. Nanog is well-known for its expression in embryonic stem 
cells, where it blocks the differentiation process (Saunders et al, 2013).Both radial glial 
cells and astrocyte precursors are actively dividing cells; the radial glial cells produce 
neurons, astrocytes, and oligodendrocytes in a context and time-dependent manner, while 
astrocyte precursors produce more astrocytes (Ge et al, 2012). Therefore, it is no surprise 
that both radial glial and astrocyte precursors contain factors important in controlling 
proliferation, including the androgen receptor, Nanog, TCF7L2, AP2α, E2F1, SREBP1, 
SREBP2 and Sox10 (Bengoechea-Alonso & Ericsson, 2016; Hashimoto et al, 2016; 
Helin, 1998; Ishimoto et al, 2010; Melnikova et al, 2010). Negative regulators of 
proliferation were also found, including CREB1 and PPARα (Cimini & Ceru, 2008; 
Perry et al, 2004).The list of regulatory factors in radial glial cells appeared to contain 
proteins that were positive regulators of proliferation, while the list of factors from 
astrocyte precursors contained both positive and negative regulators of proliferation. 
 
A second functional category that became apparent in the investigation of proteins that 
regulate expression of transcription factors found in radial glial cell and astrocyte 
precursors was that of lipid biosynthesis. For instance, the androgen receptor enhances 
the expression of cholesterolgenic enzymes by regulating SREBP2 activation, USF1 is 
critical for lipid and glucose metabolism, LXRα is involved in sterol metabolism and 
PPARα, CREB1, and SOX10 are all involved in regulating expression of proteins 
involved in sterol biosynthesis (Hashimoto et al, 2016; Kim et al, 2010; Lemberger et al, 
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2008; Naukkarinen et al, 2005). Finally, NRF2 plays a dual role, increasing synthesis and 
catabolism of cholesterol in liver (Chambel et al, 2015; Wu et al, 2012). Lipid 
biosynthesis and metabolism is critical for all living cells. Whereas the body maintains 
cholesterol homeostasis through a lipoprotein shuttle in which lipids made in the liver are 
transported to other organs and tissues via the bloodstream, the blood-brain barrier 
prohibits this process; hence the brain is responsible for its own lipid biosynthesis 
(Pfrieger & Ungerer, 2011). Although cholesterol synthesis takes place in both neurons 
and glial cells in the developing nervous system, it is confined primarily to the glial cells 
in the mature nervous system (Goritz et al, 2002). In the developing nervous system, 
cholesterol and its carrier protein, apolipoprotein E, are released from astrocytes and play 
a critical role in synaptogenesis (Goritz et al, 2005; Mauch et al, 2001). 
 
The final functional category identified were factors that play a critical role in 
inflammatory signaling. For instance, the androgen receptor has been shown to regulate 
both macrophage infiltration as well as expression of pro-inflammatory factors, PPARα 
and LXRs appear to work in conjunction with glucocorticoid receptors using a number of 
mechanisms to regulate inflammatory responses in macrophages and lymphocytes, 
SREBPs are known to increase IL-1β expression and activate inflammasome activity, and 
a number of factors we identified in our datasets (Nanog, BAPX1, NFIC,CREB1 and 
NRF2) have been identified as anti-inflammatory (Cyster et al, 2014; Duan et al, 2013; 
Glass & Ogawa, 2006; Lai et al, 2012; Pardo et al, 2016). Inflammatory mediators 
normally associated with disease processes may also play roles in the normal 
development of the nervous system. A good example of a factor that plays multiple roles 
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in nervous system development and inflammation is the cytokine superfamily, IL-6. The 
IL-6 superfamily includes IL-6, cardiotrophin 1 (CT-1), oncostatin M (OSM), IL27, and 
leukemia inhibitory factor (LIF) and is marked by the use of a common receptor, gp130, 
in the signaling process (Dixon et al, 2010). This class of cytokines is also referred to as a 
neuropoietic cytokine precisely because it has many of the pleiotropic effects of a 
neurotrophin but signals through cytokine receptors rather than the receptor tyrosine 
kinases typically associated with neurotrophins (Stolp, 2013). The IL-6 family has been 
implicated in glial fate switching, differentiation of all three major cell types in the 
developing nervous system, neurite outgrowth, synaptogenesis and maintenance of 
synapses, and survival (Adachi et al, 2005; Barnabe-Heider et al, 2005; Gadient & Otten, 
1997; Gregg & Weiss, 2005; Islam et al, 2009; Nakashima et al, 1999; Oh et al, 2010; 
Pickering & O'Connor, 2007; Stolp, 2013; Sun & He, 2010). The possibility that some of 
the pathways and molecules we have identified in our datasets as also utilized in 
inflammatory mediation is therefore not far-fetched. 
 
Astrocytes have a multitude of roles in the developing nervous system and are becoming 
increasingly more important as a factor underlying many diseases when these roles are 
impaired. They can act as neural stem cells within subpopulations of brain regions during 
development, regulate cerebral blood flow at the vascular interface, store glycogen, 
transport water, take in extracellular potassium during intense synaptic functions and 
regulate synapses by the uptake of excess extracellular neurotransmitters (Halassa et al, 
2007; Rossi & Volterra, 2009). Although extensively studied, traditional astrocyte 
analysis has not described how subtypes of astrocytes function differently during 
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development or the multiple origins and the heterogeneity that underlie glial development 
until recently (Tabata, 2015). This gap has been mainly due to lack of tools to isolate 
wild-type astrocytes for systematic studies. Although the present experiments shed light 
into this knowledge gap, future work will be needed to better understand expression 
changes among the diversity of different groups of astrocytes during differentiation. Also, 
the postnatal days and duration between astrogenesis chosen here were grounded on 
previous studies to understand diversity and functionality of different cells within the 
whole brain, however regional differences of rate of proliferation and timing of invading 
progenitors of astrocytes within the brain may differ between neural circuits (Khakh & 
Sofroniew, 2015). 
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CHAPTER 6: COMPARITIVE ANALYSIS OF MURINE RADIAL 
GLIA AND ASTROCYTE HISTONE ACETYLATION 
Introduction 
Previously we set out to determine potential factors and pathways that maybe necessary 
to the differentiation of astrocyte precursors from postnatal radial glia. A comparative 
analysis of the transcriptome of murine radial glial cells isolated at P0 and astrocyte 
precursors isolated at P8 indicated an enrichment of transcripts associated with 
proliferation, inflammatory pathways and lipid biosynthesis or metabolism. Although 
these cellular functions and the collective expression patterns correspond to 
characteristics found during the development of astrocytes, regulatory elements that 
control the expression of DNA at these stages are not well defined. One of these 
regulatory elements, acetylation, alters the basicity of histone proteins and disassociation 
to DNA, which epigenetically controls gene expression (Allfrey et al, 1964; Hebbes et al, 
1988). Also, methylation can regulate constricted associations of histone proteins and 
DNA (Zhang & Reinberg, 2001). This epigenetic regulation of nucleosomes can be a 
dynamic and complex process with many different acetylation sites within the histone 
octamer, containing histones H2A, H2B, H3, and H4, which is wrapped by 146 base pairs 
of DNA in an open (euchromatin) or closed (heterochromatin) chromatin structure 
(Kouzarides, 2007). Acetylation of histones is mutually influenced by methylation, for 
example, hypoacetylated chromatin is methylated on histone H4, whereas chromatin with 
increased histone H4 acetylation contain more methylated histone H3 (Annunziato et al, 
1995). Bivalent domains of specific residues of histones can also exist including lysine 9 
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of histone H3 (H3K9), which is modified by acetylation and associated with gene 
transcription in contrast to H3K9 methylation associated with gene repression (Rice & 
Allis, 2001). The functional and genetic consequence of both methylation and acetylation 
on individual genes is not known (Soliman et al, 2013). 
 
Previous studies have focused on understanding histone acetylation sites and the 
regulation of chromatin in brain cells; however have not completed comparisons of the 
epigenetic markers of whole brain radial glia and astrocyte precursors. For example, prior 
experiments have explored histone acetylation during normal brain development with or 
without pharmacological or genetic manipulation and intervention (Cho et al, 2011; 
Malik et al, 2014; Mitrousis et al, 2015). Specifically, studies have shown that proper 
brain development and radial glial proliferation is mediated by Histone Deacetylase 1 
(HDAC1) and HDAC3, enzymes shown to be important for regulating acetylation of 
H4K12 and H4K16 in Xenopus (Gao et al, 2016; Tao et al, 2015). A possible mechanism 
of this deacetylation-mediated proliferation and appropriate neurogenesis may be due to 
control of differentiation signaling pathways, like bone morphogenetic protein (BMP) 
signaling in mouse radial glial cells, where pharmacological approaches show that 
HDACs transcriptionally inhibit Bmp2 (Shaked et al, 2008). Astrocyte differentiation is 
also suppressed by HDAC3 and may compete with an acetylation enzyme, p300, to 
modulate H3K27 acetylation in the enhancer region of genes associated with 
oligodendrocyte lineage (Norwood et al, 2014; Zhang et al, 2016a).  
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While the acetylation-mediated gene regulation and control of proliferation or 
differentiation has been shown on different lysine residues of histone core proteins, 
acetylation of histone H3 has been the most extensively studied in astrocytes. Potent 
HDAC inhibitors have resulted in an increased astrocyte differentiation in P2 to P4 rat 
brains which coincides with increased H3 acetylation at the same dose (Lee et al, 2016). 
This may be important for the transcription factor binding of STAT3 to H3 acetylated 
regions in the promoter of Gfap, a marker of astrocyte differentiation (Asano et al, 2009). 
It has been shown that STAT3 binds along with p300 to the promoter region and exon 1 
of the Gfap gene when H3K9 acetylation occurs following differentiation (Cheng et al, 
2011). During the proliferation of rat astroglioma cells in vitro, H3K9 hyperacetylated 
regions and a corresponding increase of transcription factor binding of EGR-1 are found 
at the promoter region of a neurotrophic factor gene, Gdnf (Yu et al, 2014). Also, H3K9 
acetylation, EGR-1 binding and Gdnf expression and mediated proliferation was 
decreased when treated with HDAC inhibitors (Zhang et al, 2014a). Finally, to 
understand the neuroprotective mechanisms of acetate supplementation in different 
inflammatory brain conditions, increase of H3K9 acetylation was seen in acetate-treated 
astrocyte cultures, likely linked to the upregulation of anti-inflammatory gene 
transcription (Soliman et al, 2013). These studies have indicated evidence for the basis 
that histone acetylation is associated in radial glial proliferation and modulation of 
astrocyte differentiation. However, a full analysis has not been completed during the 
stages of proliferation and differentiation of radial glial cells and astrocyte precursors. 
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Since previous studies have shown that H3K9 acetylation is an important regulatory 
element during the differentiation of astrocytes, understanding genes associated with this 
post-translational histone modification will help to better understand the potential 
mechanism of gene regulation of important factors during the differentiation of radial glia 
and astrocytes in brain development. Chromatin immunoprecipitation using an antibody 
against H3K9 acetylation coupled with high throughput sequencing (ChIP-seq) analysis 
has been shown to be a powerful tool to identify acetylated sites of genes (Furey, 2012; 
Park, 2009). This analysis, along with prior RNA-seq studies will facilitate robustness in 
classification of important regulation and transcription of genes and pathways that are 
critical in astrocytes. 
 
ChIP with AcH3K9 antibody immunoprecipitates active gene regions 
Initial publications have shown the post-translational acetylation of H3K9 to regulate 
several genes in astrocytes. These preliminary studies have not reported whole genome 
H3K9 acetylated regions. Prior to sequencing acetylated regions of the whole genome, an 
initial study was needed to validate genes that are known to be active or inactive from the 
current samples. Chromatin from radial glial cells and astrocyte precursors was isolated 
by ChIP experiments. Replicate ChIP-qPCR experiments show that AcH3K9 IP 
antibodies bind and pull down high and medium expressing housekeeping genes (Gapdh 
and Cdkn1a, respectively) but not untranslated regions of chromosome 6 (Untr6) gene 
desert in both cell types (Figure 28). Since binding events indicate that high and medium 
expressing genes and a negative control region for H3K9 acetylation association are 
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appropriate and reproducible, these samples support the hypothesis that H3K9 acetylation 
corresponds to upregulation of gene expression. 
 
 
Figure 28: ChIP-qPCR validation. 
Control experiments comparing AcH3K9 binding in regions that are known to be active 
or inactive. Binding events per 1000 cells were detected and plotted in duplicate for each 
sample for untranslated regions of chromosome 6 (Untr6), cyclin dependant kinase 
inhibitor 1a (Cdkn1a) and glyceraldehyde 3 phosphate dehydrogenase (Gapdh). 
 
Alignment of active regions in Radial glia and Astrocyte precursors 
To distinguish the open chromatin regions within murine radial glial and astrocyte 
precursors, chromatin immunoprecipitation was performed using the AcH3K9 antibody 
tested above. A sequence analysis of 50 nucleotide reads was completed along with 
alignment using the BWA algorithm with a purity filter (Illumina Hi-Seq) and duplicate 
removal. The density of fragments was determined in continuous 32 nucleotide-long bins 
following in silico 3’ extension to 150 – 250. 
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Quantification and genome-wide distribution of active regions in radial glial and 
astrocyte precursor cells 
To quantify the peaks found following mapping and aligning of each gene, SICER (Zang 
et al, 2009), a peak calling algorithm typically used to study extended regions of the 
genome with histone modifications, was used to identify significant enrichment in 
AcH3K9 immunoprecipitated samples compared to random background. The IgG input 
control peaks were used to determine false positive ChIP peaks and estimate background 
for each sample of radial glial and astrocyte precursor cell. Numbers of active regions 
(overlapping intervals of fragment density above threshold) were counted based on their 
proximity within 10,000 nucleotides of the annotated genomic locations. Genes with 
active regions were compared and unique gene lists were compiled for radial glial cells 
and astrocyte precursor cells. Replicate samples show high overlap of genes with active 
regions, a 93% commonality in active regions of radial glial cells and 92% in astrocyte 
precursor cells. Also, among all samples, active regions are mostly found within the gene 
at 56% as opposed to upstream or downstream non-coding regions, with 57% and 64% in 
radial glial and astrocyte precursor cells, respectively.  
 
It is crucial for acetylation of H3K9 distribution to be present near the promoter and 
transcription start site for the initiation of transcription (Guenther et al, 2007). 
Interestingly, a visual representation of this genome-wide distribution indicates active 
regions are found near the transcription start site in both radial glial and astrocyte 
precursor genes (Figure 29). In fact, when calculating the percent of active regions, 79% 
and 76% of active regions were found at the transcription start site or within 2000 base 
pairs downstream. 
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Figure 29: Active acetylated H3K9 regions throughout the genome. 
Regional location and peak density (y axis) surrounding the transcriptional start site (0) 
by16,000 base pairs for both replicates (red and black dots) in the radial glia (P0 cells) 
and astrocytes (P8 cells) represented by a scatter plot. Analysis completed by Sadhna 
Rao. 
 
Comparison of Radial glial cells and Astrocyte precursors 
To understand the differences of genes associated with H3K9 regulatory elements in 
radial glial cells compared to astrocyte precursor cells, the number of genes with 
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associated H3K9 active regions above background levels were totaled and overlap of the 
list of genes were reported between radial glial cells and astrocyte precursors. The ChIP-
seq analysis revealed14,798 total genes with H3K9 active regions in the GLAST positive 
cells, however 566 radial glial genes and 396 astrocyte precursor genes were unique to 
each of these cell types, suggesting that there are subsets of genes that are epigenetically 
regulated differently with H3K9 acetylation in radial glial cells and astrocyte precursors 
(Figure 30). Since previous RNA-seq experiments have been completed using the same 
cell types used during ChIP-seq experiments, differences in the overlap of genes can be 
compared between the 2 techniques. To understand the differences of genes associated 
with H3K9 active regions to the gene transcripts of radial glial cells and astrocyte 
precursor cells, the RNA-seq and ChIP-seq gene lists were compared. When comparing 
this gene list for radial glial cells 10,325 genes were commonly acetylated and 
transcribed, however 5,039 genes were only H3K9 acetylated and a different set of 3,634 
genes were transcribed. Also, a comparison of genes from astrocyte precursors that are 
H3K9 acetylated and transcribed shows 10,271. However, 4,923 genes were H3K9 
acetylated, but not transcribed and 3,372 genes were transcribed but not acetylated 
(Figure 31) Although over half of the genes in radial glial cells and astrocyte precursors 
are H3K9 acetylated and transcribed, many genes are H3K9 acetylated, but not 
transcribed. Conversely, there are sets of genes in both radial glial cells and astrocyte 
precursor cells that are transcribed, but not H3K9 acetylated. This data would suggest 
that H3K9 regulatory elements are associated with some genes that are expressed, 
however, this marker is not sufficient to induce gene expression nor does it define gene 
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expression. This data supports the hypothesis that the regulatory control of the expression 
of DNA at these stages dynamic, complex and are not well defined. 
 
 
Figure 30: Comparison of H3K9 acetylation of radial glial and astrocyte precursor 
cells 
Venn diagram of the number of common (brown) and unique genes associated with 
H3K9 active regions for radial glia (blue) and astrocyte precursor (yellow) datasets. 
 
 
 
Figure 31: Comparison of ChIP-seq and RNA-seq datasets 
Venn diagrams of the number of common (brown) and unique genes between ChIP-seq 
active regions (blue) and RNA-seq genes (yellow). 
 
A subset of genes were viewed in the Integrated Genome Browser (IGB) to confirm 
active region peaks for individual genes show representative peaks at transcriptional start 
sites and have measurable peak densities for differential comparisons. Several genes of 
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interest were examined including a radial glial gene like, Nfatc2 and an astrocyte 
precursor gene like Tlr9 (Figure 32) 
 
 
Figure 32: Interactive Genome Browser (IGB) view of example active regions. 
Duplicate sample peaks shown in blue are from astrocyte precursor cells and duplicate 
sample peaks shown in red are radial glial cells. Input IgG negative control peaks are 
shown in grey. Nfatc2 gene is mapped on the antisense strand so that the 5’ region is on 
the right of the diagram. Note the increase in peak density in Nfatc2 proximal promoter at 
the far 5’ end of the gene of radial glial samples compared to lower astrocyte precursor 
peaks.Tlr9 gene is mapped to the sense strand so that the 5’ region is left of the coding 
region (black rectangle). Note the increase in peak density in Tlr9 proximal promoter at 
the 5’ end of the gene in astrocyte precursor samples compared to lower radial glial 
peaks. Increased peaks are displayed in Tlr9 gene of astrocyte precursor samples 
compared to radial glial cell samples. 
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Pathway analysis genes with H3K9 acetylated regions in Radial glial cells and 
Astrocyte precursor cells 
Since many transcription factors play major roles in signaling pathways and are shown to 
be important in this dataset, it is important to analyze pathways associated with these 
factors. To further the understanding of molecular functions of genes with active regions 
in radial glia or astrocyte precursors, we performed pathway analysis using the Ingenuity 
Pathway Analysis tool to identify the canonical pathways based on datasets from radial 
glial cells and astrocyte precursor cells. Regulated genes revealed the highly statistically 
significant pathways based on a p-value less than 0.05 and FDR less than 0.5 (Table 12). 
Well-known growth factor signaling pathways in the radial glial cells, including calcium 
signaling, Wnt signaling, GNRH signaling and CREB signaling matched a significant 
number of genes with active regions. Genes in astrocyte precursor cells were identified as 
playing a role in inflammatory pathways, including NF-κB signaling, Toll-like receptor 
signaling and IL-8 signaling were detected (Table 12).  
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Table 12: Ingenuity pathway analysis of differential active regions in radial glial and 
astrocyte precursor cells. 
 
 
Transcription factor binding analysis of genes with active regions 
To identify upstream factors that may interact with H3K9 acetylated chromatin on the 
promoter region, transcription factor analysis was completed to understand the 
transcriptional regulators that potentially may bind to consensus site genes within these 
target datasets. The entire gene list of H3K9 acetylated genes were used to identify 
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transcription factors that bind to these genes. Transcription factor identification was 
completed using the Transcription Regulation algorithm from the commercial software 
MetaCore (GeneGo, Inc, St. Joseph, MI) which is based on manual curation. This 
algorithm generated networks of our gene lists centered on transcription factors known to 
directly bind these genes. Transcription factors were ranked according to their p-value 
and number of genes in our list compared to total genes that it may bind (seed nodes). 
The top 25 statistically significant transcription factors that have been shown to regulate 
genes in radial glial cells (Table 13) or astrocyte precursors (Table 14) were indicate by 
the MetaCore Transcription Factor analysis. Interestingly, many of the transcription 
factors identified as potential regulators of the genes in H3K9 active regions were similar 
between radial glial and astrocyte precursors. These factors were marked with a “(C)”. 
There were some differences in potential transcription factors, which suggest differences 
in the cofactor binding and interactions of transcription factors for the expression of these 
genes. 
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Table 13: Metacore transcription factor regulation analysis of active regions from radial 
glial cells 
 
 
 
 
 
 
 
124 
 
Table 14: Metacore transcription factor regulation analysis of active regions from 
astrocyte precursor cells 
 
 
Discussion 
Since aforementioned experiments have shown that H3K9 acetylation is important for 
gene expression during the differentiation of astrocytes, a genome-wide analysis of this 
regulatory element will help to better understand the potential mechanism of gene 
regulation of important astrocyte differentiation factors in brain development. In these 
studies, ChIP of H3K9 acetylation was shown to appropriately isolate control 
regions/genes. Also, it is possible to map and align H3K9 active regions to the genome 
and define the distribution of active regions to quantify the density of the peaks. Within 
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the coding regions of the genes, H3K9 acetylation modifications are mainly enriched in 
the near the transcription start site.  
 
Pathway analysis of this data has bolstered the idea that genes identified to play a role in 
inflammatory pathways are also important factors during astrogenesis stages. Many 
previous reports corroborate the pathways from the current study. In radial glial cells, 
Wnt signaling is required for stabilizing vascular networks, self-renewal and 
neurogenesis following spinal cord injury (Briona et al, 2015; Gan et al, 2014; Ma et al, 
2013). CREB signaling has shown to be neuroprotective in reactive glia (Pardo et al, 
2016) along with decreases calcium excitability (Eraso-Pichot et al, 2016). Calcium 
signaling is controlled by TRPC in radial glia and regulates neurogenesis and migration 
of neurons (Molnar et al, 2016; Rash et al, 2016). Evidence of direct gonadotrophin-
releasing hormone interaction with astroglial cells has been shown along with 
localization of protein kinase C, modulated by MARCKS during postnatal brain 
development (Baroncini et al, 2007; Chen & Hillman, 1994; Weimer et al, 2009). In 
astrocyte precursors, nuclear factor-κB-dependent inflammation is a major pathway in 
Parkinson’s disease, Alzheimer’s disease and Huntington’s disease (Ben Haim et al, 
2015; Hsiao et al, 2013; Pal et al, 2016). Also, the IL-8 inflammation pathway in 
astrocytes correlates with seizure frequency in brain tissue (Pernhorst et al, 2013). 
Endothelin-1 and its receptors are not normally expressed in astrocytes, however when 
they adapt to reactive phenotypes, high levels are expressed (Hostenbach et al, 2016). 
Finally, many pathways converge in to ERK/MAPK signaling and have crucial roles in 
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demyelinating inflammation and other astrocyte diseases in the central nervous system 
(Okazaki et al, 2016). 
 
Transcription factor regulation analysis of this data has identified factors important in 
both radial glial cells and astrocyte precursors, however, interestingly there are factors 
potentially differentially regulating radial glial genes or astrocyte precursor genes. 
Factors potentially binding and regulating radial glial cells include WT1 (Wilm’s Tumor 
1) and NANOG. WT1 has been shown to be overexpressed in primary astrocytic tumors, 
however this protein expression cannot distinguish between proliferating tumor cells and 
reactive astrocytes (Bourne et al, 2010; Oji et al, 2004). NANOG, similarly to Wnt 
signaling regulates astrocyte proliferation following spinal cord injury (Gu et al, 2016). 
Also, NANOG has the ability, as a stemness marker, to induce dedifferentiation of p53-
deficient mouse astrocytes into glioma cells (Moon et al, 2011). Both of these factors 
have the ability to induce proliferation in certain context, however have been shown to be 
involved in disease states. Factors potentially binding and regulating astrocyte precursor 
cells include STAT3 and SMAD3. STAT3 as mentioned above, has a direct role in gene 
regulation in astrocytes. It is not surprising that our analysis also detected potential 
STAT3 regulation of astrocyte genes. This transcription factor has been identified as 
playing a role in IL-6 inflammatory pathways, however, it has other roles in cell growth, 
differentiation and survival as well (Hirano et al, 2000; Hong & Song, 2014). SMAD3 is 
a factor that is identified to play a role in inflammatory pathways and also important 
factors during astrogenesis stages. SMAD3 is associated with the TGF-β pathway that 
controls differentiation of radial glia into astrocytes (Stipursky et al, 2012). SMAD3 
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deficiency increases cortical and hippocampal neuronal loss following traumatic brain 
injury and increases Parkinson’s disease pathology (Tapia-Gonzalez et al, 2011; Villapol 
et al, 2013). Both of these factors have the ability to induce differentiation of astrocytes, 
however have been shown to have a more direct involvement with inflammatory brain 
diseases. Many of the other transcription factors are identified as playing a role in 
inflammatory pathways as well including, CREB1, STAT1 and NFκB. These factors do 
not seem to have the potential of differentially regulating radial glia or astrocyte 
precursor gene expression however, a combination of these may have differential roles in 
proliferation and differentiation (Cheng et al, 2013). Further experiments to understand 
acetylation during these events and the associated regulatory factors will give better 
insight to how the complexity of transcription is regulated during brain development.  
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CHAPTER 7: PHOSPHODIESTERASE 10A INHIBITOR, MP-10 (PF-
2545920), PRODUCES GREATER INDUCTION OF C-FOS IN 
DOPAMINE D2 NEURONS THAN IN D1 NEURONS IN THE 
NEOSTRIATUM 
Introduction 
In previous chapters, this dissertation has focused on the regulation of glial cell 
phenotypes by α-synuclein and genomic alterations associated with astrogenesis. As 
mentioned earlier, the modulation of inflammatory processes within glial cells are a key 
feature of PD, but do not directly account for the hallmark symptoms of PD. To better 
understand deficits in locomotor activity, understanding the cellular signaling processes 
in different cell types within the basal ganglia is necessary. Pathology of dopamine 
neurons in the SN of the basal ganglia defines PD (Ehringer & Hornykiewicz, 1960; 
Hirsch et al, 1988) and the loss of these cells discontinues delivery of dopamine to post-
synaptic cells, such as the medium spiny neurons, causing motor symptoms (Damier et al, 
1999). However, distinct cell populations with different dopamine receptor activity, 
stimulatory and inhibitory pathways,  defined by D1 receptors and D2 receptors 
respectively, are present (Gerfen, 1992). During normal function, these cells require 
balanced activation, and in PD, the loss of SN dopamine neurons leads to disinhibition of 
the indirect pathway and the loss of stimulation of the direct pathway, which results in the 
overall decrease in basal ganglia output. One enzyme downstream of the dopamine 
receptor signaling pathway, PDE10A, has been shown to be uniformly expressed in all 
medium spiny neurons and show decreased protein levels in PD (Kleiman et al, 2011; 
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Niccolini et al, 2015; Seeger et al, 2003). When this enzyme is inhibited, an unbalanced 
induction of medium spiny neuron activity was seen (Strick et al, 2010). Studies such as 
these are needed to further characterize and confirm the molecules with unbalanced 
activation in the basal ganglia circuitry. Therefore, the following studies were completed 
to identify mechanisms that regulate basal ganglia cell activity and may affect PD 
pathology and the overall decrease of motor circuitry. 
 
The medium spiny neurons (MSN) of the neostriatum are the primary target of 
antipsychotic and anti-parkinsonian medications. Specifically, these drugs target the Gαi-
coupled dopamine D2 family of G protein-coupled receptors on the MSNs (Perreault et 
al, 2011). Morphological and functional studies have shown that the D2 receptor-
expressing MSNs constitute the striatopallidal pathway whereas the Gαs-coupled D1 
expressing cells form the striatonigral pathway (Gerfen, 1992). Classical antipsychotic 
drugs are thought to produce their efficacy by antagonizing the D2 receptors (Kapur & 
Mamo, 2003). However, these drugs also induce extrapyramidal motor side effects by 
reducing basal ganglia output (Parr-Brownlie & Hyland, 2005). Although the newer, so-
called atypical antipsychotics have a reduced liability to trigger extrapyramidal side 
effects, they induce intolerable metabolic side effects (Manu et al, 2012). Therefore, it 
remains critical to identify additional therapeutic mechanisms for treatment of psychotic 
symptoms associated with schizophrenia and other psychiatric disorders. 
 
Phosphodiesterases (PDEs) are a family of enzymes that cleave cyclic nucleotides and 
thereby regulate second messenger signaling casacades (Sharma et al, 2013). PDE10A, 
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like several other PDEs, cleaves both cyclic adenosine monophosphate (cAMP) and 
cyclic guanosine monophosphate (cGMP) to AMP and GMP, respectively (Wilson & 
Brandon, 2014). PDE10A is particularly relevant to the basal ganglia system because it is 
highly enriched in MSNs (Kleiman et al, 2011; Seeger et al, 2003). MP-10 (also known 
as PF-2545920; 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-
yl)phenoxy)methyl)quinoline) is a potent and selective PDE10A inhibitor (PDE10i) both 
in vitro and in vivo (Schulke et al, 2014). Treatment with MP-10 increases intracellular 
concentrations of cAMP/cGMP, augmenting dopamine D2 receptor antagonist- and 
dopamine D1 receptor agonist-mediated effects (Grauer et al, 2009; Schmidt et al, 2008). 
Given that dopamine D2 receptor inhibition is a pharmacological activity shared by all 
antipsychotic drugs, PDE10i have been proposed as a new class of therapeutics to treat 
psychoses (Strick et al, 2010).  
 
The PDE10A knockout mice show reduced locomotor activity (Siuciak et al, 2006; 
Siuciak et al, 2008). Hence, we hypothesize that although PDE10i will affect activity of 
all MSNs, it may induce relatively greater activation of D2(+) MSNs. The present set of 
studies tested this hypothesis using MP-10 as a pharmacological probe. We assessed c-
Fos immunoreactivity as a marker of increased neuronal activity in two sub-regions of 
the neostriatum, the dorsolateral and dorsomedial striatum, preferentially regulated by 
dopamine D2 and D1 receptors, respectively (Merchant et al, 1994). The regional pattern 
of c-Fos induction by MP-10 was compared to that produced by acute treatment with 
prototypical D2 antagonist, haloperidol and D1 agonist, SKF82958. Finally, to directly 
confirm this effect, we utilized the bacterial artificial chromosome (BAC) transgenic 
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Drd1a-tdTomato mice line 6 (Ade et al, 2011) to assess co-localization of c-Fos 
immunoreactivity in MSN populations that express the D1 receptor or those without the 
D1 receptor. In these mice, the expression of the fluorescent reporter tdTomato is under 
the regulation of the Drd1a gene and the reporter is expressed with high selectivity and 
specificity only in D1(+) MSNs (Ade et al, 2011), thereby providing a direct method to 
assess the induction of c-Fos in both the D1 or D2-expressing sub-populations of MSNs. 
 
MP-10 dose-dependently increased c-Fos expression in the rat striatum 
Figure 33A shows the c-Fos immunopositive cells at two different magnifications 
following MP-10 at 30 mg/kg, PO, to rats. A statistically significant, dose-dependent 
increase in c-Fos immunopositive cells was observed in both the DLS and DMS at 10 and 
30 mg/kg of MP-10 (Figure 33B). Notably, the c-Fos signal density was higher in the 
DLS than the DMS at both 10 and 30 mg/kg doses. The c-Fos dominance index derived 
by subtracting the DMS signal from that in the DLS confirmed that MP-10 treatment at 
10 and 30 mg/kg significantly produced a DLS-dominant effect (Figure 33C). There was 
no significant induction of c-Fos in additional brain regions examined (Figure 33D). 
Hence, all subsequent studies focused on the DLS and DMS c-Fos expression. 
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Figure 33: MP-10 dose-dependently and selectively induces c-Fos expression in the rat 
neostriatum. 
A) Representative micrographs of c-Fos immunopositive nuclei in the neostriatum of a 
rat treated with MP-10 at 30 mg/kg, PO. The left panel shows the neostriatum with DLS 
and DMS, outlined. The two right panels show c-Fos-positive nuclei in the DLS and 
DMS at higher magnification. Magnification bars = 200 μm. B) Quantitative analysis of 
c-Fos immunoreactive cell density in the DLS and DMS. Each point represents the group 
mean ± SEM. * p<0.05 versus the vehicle. C) The c-Fos dominance index derived from 
data in Figure 1B is shown as adjusted mean ± 95% confidence interval for each group. 
*p<0.05 versus the vehicle. †p<0.05 versus the DMS signal. D) Quantitative analysis of 
c-Fos signal density in other brain regions following treatment with MP-10. Each bar 
represents the group mean ± SEM. PrL, Prelimbic Cortex; IL, Infralimbic Cortex; AcbSh, 
Accumbens Shell; Hipp, Hippocampus. 
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Dopamine D2 receptor inhibition and D1 receptor activation show a regional 
preference in c-Fos expression 
SD rats treated with haloperidol (0.3, 1 or 3 mg/kg, PO) or SKF82958 (0.5, 1 or 2 mg/kg, 
PO) dose-dependently induced c-Fos in the DLS and DMS. The c-Fos dominance index 
demonstrated that like MP-10, the dopamine D2 receptor antagonist, haloperidol, favored 
the activation of the DLS (Figure 34A and 34B), whereas the dopamine D1 receptor 
agonist, SKF82958, favored that in the DMS (Figure 34C and 34D). 
 
The cross-rodent species consistency of the c-Fos dominance index was established in the 
C57BL/6 mouse striatum in which haloperidol (2 mg/kg, IP) or SKF82958 (3 mg/kg, IP) 
produced an identical regional pattern of c-Fos induction (Figure 34E-G). 
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Figure 34: c-Fos induction in the DLS and DMS by haloperidol or SKF82958. 
Panels A and C compare c-Fos dominance index in the rat neostriatum by haloperidol 
(0.3, 1 or 3 mg/kg, PO; Panel A) or SKF82958 (0.5, 1 or 2 mg/kg, PO; Panel C) and their 
respective vehicle. Data are shown as adjusted mean ± 95% confidence interval. *p<0.05 
versus the vehicle. †p<0.05 versus the DMS signal. Panels B and D show representative 
photomicrographs of c-Fos positive nuclei in the DLS and DMS following treatment with 
haloperidol (3 mg/kg, PO; Panel B) or SKF82958 (2 mg/kg, PO; Panel D). Magnification 
bars = 200 μm. E) c-Fos dominance index following treatment of C57BL/6 mice with 
vehicle (IP), haloperidol (2 mg/kg, IP) or SKF82958 (3 mg/kg, IP) shown as adjusted 
mean ± 95% confidence interval. *p<0.05 versus the vehicle, †p<0.05 versus the DMS. 
Panels F and G show representative photomicrographs corresponding to the data in 
Figure 2E for effects of haloperidol (Panel F) and SKF82958 (Panel G). Magnification 
bars = 200 μm. 
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MP-10-induced c-Fos expression is greater in D2+ MSNs than in D1+ MSNs of the 
Drd1a-tdTomato mouse 
To directly assess MP-10-induced c-Fos expression within the D1(+) and D1(-) (i.e., 
primarily D2(+)) MSN populations, colocalization experiments were conducted in BAC 
transgenic Drd1a-tdTomato mice treated with MP-10 (3 or 10 mg/kg, IP). We removed 
the regional bias of our analyses by comprehensive assessment of the c-Fos signal in five 
fields encompassing the entire dorsal striatum (Figure 35C). MP-10 increased the percent 
of c-Fos expressing cells in both D1(-) and D1(+) cells, when compared to vehicle 
treatment, but there was no statistical difference between the doses of MP-10 assessed 
(Figure 35A and 35B). At 3 mg/kg, 45% of D1(+) cells expressed c-Fos and at 10 mg/kg, 
44% of D1(+) cells were c-Fos positive. On the other hand, 54% and 58% of D1(-) were 
c-Fos positive at 3 and 10 mg/kg of MP-10, respectively. The percent of c-Fos induction 
within D1(-) neurons was significantly greater than that in D1(+) neurons, following 10 
mg/kg of MP-10; although a similar trend appeared at 3 mg/kg of MP-10 (p = 0.071) 
(Figure 35C). 
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Figure 35: MP-10 produces greater induction of c-Fos in D1(-) cells in the dorsal 
neostriatum of the BAC transgenic Drd1a-tdTomato mouse. 
A and B) The mean ± SEM for the percent of D1(-) and D1(+) cells with and without c-
Fos are reported for each treatment group. *p<0.05 versus the vehicle. C) c-Fos positive 
cell counts were normalized to D1(+) cells or D1(-) cells. The adjusted mean percent of 
c-Fos positive cells and ± SEM are reported for each dose group. *p<0.05 indicates a 
statistically increase in c-Fos in D1(-) cells when compared to D1(+) cells. 
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Discussion 
The present studies utilized a combination of pharmacological and genetic tools to test 
the hypothesis that PDE10A inhibition produces greater activation of D2(+) 
striatopallidal pathway than D1(+) striatonigral pathway. Using c-Fos as a marker of 
neuronal activation and a selective PDE10i tool, MP-10, we provide two major but 
complementary lines of evidence in support of this hypothesis. First, like the effects of 
the D2 inhibitory ligand, haloperidol, the effects of MP-10 were greater in the DLS than 
in the DMS in both the rat and the mouse. Second, and more directly, MP-10 treatment 
produced greater induction of c-Fos in D1(-) MSN neurons in a BAC transgenic mouse 
where only D1(+) cells are fluorescently labelled. Since MSNs represent 95% of cells in 
the striatum, it can be deduced that D1(-) cells are predominantly D2(+) cells (Kemp & 
Powell, 1971), which respond to a greater extent to PDE10A inhibition by MP-10.  
 
MP-10 is a well-characterized pharmacological tool for PDE10A inhibition (Schmidt et 
al, 2008). At doses used in the present set of experiments, MP-10 is shown to produce 
robust biochemical and behavioral alterations in the rat and the mouse (Grauer et al, 
2009; Megens et al, 2014; Sotty et al, 2009). Characterization of the c-Fos induction 
within sub-regions of the striatum was performed on the basis of the previously reported 
greater sensitivity of the DLS to D2 antagonism and the DMS to D1 agonism (Merchant 
et al, 1994). Although the focus on DLS and DMS may have introduced a regional bias in 
our initial results, we ultimately removed any confounds of regional selection by broadly 
surveying the dorsal striatum in the Drd1a-tdTomato mouse study (vide infra). Indeed, 
MP-10 produces significantly greater c-Fos induction in the DLS than the DMS, a pattern 
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similar to that produced by the prototypical D2 antagonist, haloperidol, at doses that 
selectively occupy the D2 receptor. On the other hand, the activation of the D1 receptor 
by SKF82958 favored c-Fos induction in the DMS. These data are in agreement with a 
recent report (Gentzel et al, 2015) demonstrating greater sensitivity of the DLS to MP-10-
mediated activation of c-fos, arc, and egr-1 mRNA. 
 
To directly assess MP-10 induced c-Fos in D1(+) versus D2(+) MSNs, we took 
advantage of the BAC transgenic mice expressing a fluorescent reporter (td-Tomato) 
exclusively in the D1(+) MSNs with negligible rates (0.7%) of false negativity of the 
transgenic reporter (Ade et al, 2011). Nearly 60% of total cells counted were positive for 
td-Tomato in vehicle-treated animals. Since >95% of neostriatal cells are MSNs, we 
presumed that td-Tomato negative cells are predominantly dopamine D2 receptor 
containing MSNs. Thus, a single mouse line allowed us to assess MP-10-induced c-Fos 
expression in D1(+) and D2(+) MSNs. The percent of D1(+) neurons did not differ 
among five fields examined. Since the mouse metabolizes MP-10 at a faster rate after 
oral administration (data not shown), we tested MP-10 effects via the IP route at doses 
that produce significant behavioral effects. From the percent of c-Fos-expressing cells in 
D1(+) and D1(-) MSN population, we conclude that MP-10 produces greater activation 
of the D2(+) cells. This effect was statistically significant at 10 mg/kg, IP, but missed 
significance at 3 mg/kg, IP, due to higher variability in this dose group. Numerically, the 
dose-response relationship was not robust in this study where a limited dose-range was 
tested. On the other hand, a statistically significant response was only observed at 10 
mg/kg. Future tests of a wider dose range would further assess a dose-dependent effect. 
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The small, but significantly greater effect of PDE10i in D2(+) cells is observed despite 
similar levels of Pde10a mRNA in the D1(+) and D2(+) MSNs (Fujishige et al, 1999; 
Heiman et al, 2008). Whether PDE10A protein levels or enzyme activity are different in 
the two MSN cell types is not known. Thus it appears that despite the presence of 
PDE10A in all MSNs of the neostriatum (Seeger et al, 2003), the basal tone of the 
enzyme is higher in the D2 containing striatopallidal pathway. This could be due to the 
relatively higher basal activity of the D2(+) than the D1(+) MSNs (Day et al, 2008).  
 
Our data are consistent with and extend the behavioral observations of Siuciak et al. 
(Siuciak et al, 2006) in PDE10A knockout mice. These investigators noted that PDE10A-
deficient mice display suppressed locomotor output without any reduction in striatal 
dopamine levels or dopamine turnover. They hypothesized that although PDE10A is 
expressed at similar levels in all MSNs, inhibition of PDE10A preferentially increases the 
activity of the inhibitory indirect pathway and thereby reduces motor output. This is 
somewhat borne out by the results of Strick et al. (Strick et al, 2010), who reported 
greater induction in enkephalin mRNA (a marker of striatopallidal MSN activation), than 
substance P mRNA (a marker of striatonigral MSN activation) by MP-10 treatment, 
although their method did not directly quantitate the effect of PDE10A inhibition in the 
two MSN efferent pathways. More importantly, Nishi et al. reported that PDE10A 
inhibition produces higher levels of DARPP-32 phosphorylation in striatopallidal MSNs 
than in the striatonigral neurons (Nishi et al, 2008). Direct assessment of MSN activity 
showed that PDE10A inhibition augmented cortically evoked spike activity only in 
striatopallidal and not in striatonigral MSNs (Threlfell et al, 2009). On the other hand, a 
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recent study by Gentzel et al. determined the effects of MP-10 on the two MSN 
populations by analyzing co-expression of egr-1 and substance P (i.e., striatonigral 
MSNs) or egr-1 and enkephalin (i.e., striatopallidal MSNs) and failed to see preferential 
activation of the striatopallidal pathway (Gentzel et al, 2015). The reasons underlying the 
somewhat discrepant results remain unclear but we believe that the Drd1-tdTomato 
mouse provides the most direct method to determine the relative engagement of the two 
MSN populations by a PDE10i. Overall, the preponderance of evidence from the current 
study and those cited above indicate that acute PDE10 inhibition increases the activity of 
both striatopallidal and striatonigral projections, but with a small but significant 
preference for the striatopallidal projections. Although this signature of pharmacological 
activity supports the investigation of this mechanism in psychotic disorders, it also raises 
a concern whether medically relevant antipsychotic efficacy may be produced in the 
absence of extrapyramidal side effects.  
 
In contrast to acute activation of MSNs induced by MP-10, PDE10A-deficient mice show 
overall decreased striatal excitability (Piccart et al, 2014). However, the activity of D1(+) 
versus D2(+) MSNs in PDE10A deficient mice was not assessed. Furthermore, it is 
possible that the effects of acute, short-term inhibition of PDE10A inhibition are distinct 
from a developmental deletion of PDE10A. Future studies assessing chronic effects of a 
PDE10i in wild-type mouse may further our understanding of the PDE10A-mediated 
regulation of the striatal output. 
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It is noteworthy that we failed to observe significant c-Fos induction in regions other than 
the neostriatum. Gentzel et al. reported MP-10 induced increase in c-fos but not egr-1 
mRNA in the nucleus accumbens but the effects were greater in the DLS (Gentzel et al, 
2015). Seeger et al. also failed to show activation of the nucleus accumbens shell by a 
PDE10i, despite high levels of expression of PDE10A in this nucleus (Seeger et al, 
2003). These data indicate that basal activity of PDE10A is regulated in a region and cell-
type specific manner. 
 
It is important to point out that PDE10a is not expressed in presynaptic dopamine cells or 
striatal glutamate terminals, so there are no direct effects of MP-10 on dopamine release 
via the autoregulatory presynaptic D2 receptors or glutamate activation. Previous reports 
have interrogated other striatal-enriched PDEs and have hypothesized that PDE1B or 
PDE4 favorably increase activity in D1(+) cells (Nishi et al, 2008; Reed et al, 2002). 
However, our unpublished data indicate that unlike PDE10A, the basal tone of PDE1B in 
rodents is minimal such that acute inhibition of PDE1B fails to induce c-Fos in the 
neostriatum or other forebrain regions.  
 
Although these studies have provided important evidence of apparently distinct basal 
tone of PDE10A in different brain regions and neuronal subtypes, a key limitation of the 
studies is that the effects of the PDE10i were assessed in young, healthy rodents. It is 
possible that in a model of a basal ganglia disorder such as Parkinson’s disease, 
Huntington’s disease or schizophrenia, a PDE10i may produce a distinct profile of MSN 
activation. The dynamic regulation of PDEs is indicated by a recent animal study 
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showing an increase in PDE10A expression after acute stress and protracted alcohol 
withdrawal (Logrip & Zorrilla, 2014). In future studies, it is critical to assess the 
pharmacology of PDE10A and other PDE inhibitors and their interactions in appropriate 
disease models to elucidate the role of this important family of druggable enzymes. 
Although definitive clinical implications of PDE10i effects observed in rodents are not 
fully clear, the profound activation of direct and indirect pathways indicates potential 
utility of PDE10i in the treatment of Huntington’s disease. It remains to be seen whether 
this profile of MSN activation underlies the reported antipsychotic activity or dystonia-
like side-effects of MP-10 in schizophrenic patients (Schmidt, 2012). 
 
Conclusion 
In summary, through a combination of pharmacological and genetic tools, we provide 
convergent evidence of D2 pathway dominant effects of PDE10A inhibition in rodents. 
These data augment the existing literature implicating the role of PDE10A in regulation 
of basal ganglia output and provide further insights into functional implications of 
modulation of PDE10A, an enzyme actively targeted for therapeutic development. 
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FUTURE DIRECTIONS 
The work presented here has added significant understanding toward the characterization 
of neuroinflammatory cells, like microglia and astrocytes, which cause 
neuroinflammation during the pathophysiology of PD. Fibrillar α-synuclein initiates 
classical activation and their pro-inflammatory state, which in turn may affect an 
inflammatory cascade including astrocyte reactivity and proliferation. This work is 
foundational to identifying key mechanisms of inflammation during the treatment of α-
synuclein. Based on this data, future experiments should block or decrease fibrillar α-
synuclein interactions with microglia or astrocytes. Understanding whether fibrils can be 
blocked by a therapeutic antibody (Masliah et al, 2011) or decrease interaction with a 
putative receptor (Mao et al, 2016) while testing the resulting modulation of reactivity 
within glial cell culture would inform further experiments in vivo and the future PD 
therapies. 
 
Neuroinflammatory mechanisms within activated microglia and proliferating astrocytes, 
in response to α-synuclein is a major pathology in PD. Future work in this area should 
focus on a viable therapy for both the blocking of α-synuclein aggregation/propagation 
using antibodies (Wrasidlo et al, 2016) along with the use of inhibitors to 
neuroinflammatory effects (Barnum et al, 2014) and possibly enhancing the 
neuroprotective/anti-inflammatory effects (Le et al, 2016). Neuroinflammatory effects of 
cytokines can be devastating to the surrounding cell population (McCoy et al, 2011). 
Blocking these cytokines can have attenuating effect of activation of glial cells along 
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with associated decreasing dopamine cell death (Barnum et al, 2014). The validation and 
utilization of an in vitro propagation neuronal cell assay would be important in addition 
to antibodies against both α-synuclein and neuroinflammatory cytokines, or addition of 
anti-inflammatory cytokines. Further in vitro experiments modeling α-synuclein 
propagation in the context of inflammation will help to understand if robust increases of 
transmission are seen when in the presence of inflammation. Decreasing acute pro-
inflammatory cytokines like TNFα during the initial stages of cell-to-cell transfer may 
help to slow propagation of α-synuclein and possibly decrease neuronal death and patient 
decline, however later in the disease process when patients are presenting symptoms, 
only dopamine cell regeneration or other dopamine therapies would help chronic patients. 
 
A prognostic biomarker that measures fast and slow progressors of disease would help to 
inform the correct individualized therapy for these PD patients. It is unknown whether 
patients with increased CSF cytokines progress faster than patients with baseline levels of 
inflammatory markers. Collection and evaluation of CSF constituents should be 
measured using clinically validated assays. The measurement of a CSF cytokine, like 
TNFα, would be informative of the pro-inflammatory cytokine levels and possibly the 
state of neuroinflammation in the brain. When cytokine levels in CSF are understood, 
correlations to progression of disease of individual patients can be made. If significant 
statistical correlations are found, the rate of disease progression can be monitored by CSF 
biopsy and evaluation of cytokine levels. 
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Another future direction for PD and microglia would involve Trem2 activity. A Trem2 
therapy may be of interest for the clearance of Lewy bodies. An agonist of Trem2 has 
been shown to promote phagocytosis of other misfolded proteins like Aβ plaques (Yeh et 
al, 2016). Future experiments should study the effects of Trem2 function in PD related 
models. For instance, internalization of α-synuclein following the modulation of Trem2 
levels in microglia would help to understand the role of Trem2 in α-synuclein clearance. 
Current data show that microglia react to α-synuclein by an increase in phagocytosis 
action. Both reactions of increased cytokine and uptake when in contact with α-synuclein 
would be ideal, as long as the process does not chronically ensue, as the duality of 
mechanisms are initially beneficial for neuronal survival (Barnum & Tansey, 2011). 
Also, the current data suggest that as the quantity of aggregated α-synuclein increases, 
cytokines increase. Further experiments should modulate the levels of α-synuclein prior 
to measuring phagocytosis function in vitro to understand the levels of particles that 
microglia can engulf at steady state. Other future experiments modulating many 
phagocytosis receptors in microglia will be beneficial toward the understanding of eat-me 
signaling, the connection to the intracellular inflammasome trigger and function of 
microglia mediated clearance (Codolo et al, 2013). Although other cell types were not 
studied in this work, phagocytosis of other cell types should be studied. Astrocytes are 
phagocytizing cells in non-stimulated resting states (Chung et al, 2013; Yamamoto et al, 
2013). Signaling pathways regulating astrocyte uptake such as P2X7, MERTK and 
MEGF10 signaling receptors should be modulated following aggregated α-synuclein 
treatments to confirm uptake and understand the role of these receptors. 
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Since both microglia and astrocytes responded to fibrillar α-synuclein by releasing TNFα, 
further studies should understand how these cells increase pro-inflammatory state in PD. 
Learning about the molecules and pathways involved in these glial cells may help to 
discover brain specific therapies for neuroinflammation. Recently, a brain specific 
activator of LXRs, a pathway shown to be important for microglia and astrocyte 
reactivity (Theofilopoulos et al, 2013) may promote midbrain neurogenesis. Although no 
differential expression of LXRs are seen in post-mortem dementia brains and a related 
nuclear receptor, RXR seems to increase with other markers of reactive astrocytes 
(Akram et al, 2010). LXRβ KO mice have defective development of the early midbrain 
(Sacchetti et al, 2009). Also, treatment of human embryonic stem cells with LXR 
agonists increased neurogenesis of mature dopamine neurons, and protects dopamine 
neurons in a mouse model of PD suggesting a novel therapeutic application of LXR 
ligands in PD (Steffensen et al, 2013). Also, it has been shown in another model of 
neurodegeneration that nuclear receptor agonists increase tissue repair mechanisms, 
increase phagocytosis receptors (MERTK, AXL, TREM2) and suppress pro-
inflammation (Savage et al, 2015). Based on current data in the P0 GLAST positive cells 
that show this pathway to be differentially upregulated, it would be of interest to 
understanding treatment effects of LXR agonists on the proliferation and differentiation 
in glial cells as well as the effect of this agonist on the pro-inflammatory state of glial 
cells. 
 
The current data show astrocyte proliferation is mediated by inflammatory signaling 
pathways and transcriptional activation of known inflammatory genes. Known 
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inflammation mechanisms have been demonstrated during proliferation stages of 
astrocyte development, a recapitulation of the mechanisms seen in reactivity and gliosis. 
This disordered state and feed-forward pathogenic mechanism of inflammatory 
modulating cells within the basal ganglia of the brain may cause further propagation of 
PD pathology and dopamine neuron cell death. Genetic validation of astrocyte 
involvement in PD has come from CLU and SORL1 without any mechanistic evidence 
(Gao et al, 2011; Sasaki et al, 2002). Grasping a better understanding of genetic markers 
such as these and many others from the current dataset is key to understanding 
neuroinflammation in PD. BMP and Notch signaling pathways are highly expressed 
using genetic techniques and have plenty of mechanistic experimental results, although 
low levels of astroglial cell type markers like GFAP, vimentin and heat shock protein 27 
in PD relative to α-synuclein may indicate a deficient reactivity in this disease (Tong et 
al, 2015). The current unique dataset of ChIP sequencing and RNA sequencing and future 
validation can add to the expression pattern changes previously seen in astrocytes. A 
main question pertaining to SMADs and Notch signaling transcriptional regulation and 
their potential cross-talk with other known inflammatory signaling factors like 
JAK/STAT pathways would help to elucidate the neuroinflammatory component seen 
during proliferation. Also, astrocyte markers at different stages of development and 
disease are sparse. Validation of radial glia and astrocyte markers in active regions of 
acetylated H3K9 regions would help to bolster our knowledge of these cells along with 
ontologies of genes within these regions that are differentially acetylated. It is unknown if 
there is a motif or promoter region that has been differentially acetylated within these 
cells. 
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PDE10A is modulated during the process of PD and affects dopamine signaling 
pathways, preferentially in D2 expressing neurons in the indirect pathway within the 
striatum. The current studies characterize and confirm an unbalanced activation of basal 
ganglia circuitry based on PDE10A inhibition. This circuitry is also affected by PD 
pathology and results in the overall decrease of motor circuitry. Although information has 
been elucidated PDE10A biology in the context of PD, further studies can build on this 
work to better understand PD pathobiology (Niccolini et al, 2015). Assessment of a 
broader dose regimen of PDE10i and other PDE inhibitors in disease models will help to 
elucidate the role these enzymes. It is unknown how this inhibitor may affect striatal cell 
types when PDE10A expression has declined. During the disease state, further expression 
analysis should be completed to understand if PDE10A decreases preferentially in either 
D1 expressing cells or D2 expressing cells. Long term experiments determining PDE10i 
mediated effects on chronic neuronal activation in D1 and D2 dopamine pathways, for 
instance, would increase our understanding of the activation of cells in the basal ganglia 
affecting chronic PD patients. 
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